valproic acid has been researched along with Autism in 262 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Valproic acid (VPA) induced rodent model of autism is a widely accepted and extensively used rodent model to investigate the pharmacotherapy against autism." | 9.22 | Critical Evaluation of Valproic Acid-Induced Rodent Models of Autism: Current and Future Perspectives. ( Chopra, M; Mehra, S; Seth, E; Ul Ahsan, A, 2022) |
| "In this study, based on the excitatory/inhibitory imbalance theory of autism, the time window of GABA switch, the role of K-Cl co-transporter 2 (KCC2) in adjustment GABA switch, and brain permeability to erythropoietin (EPO), the effects of postnatal -EPO and- nano- erythropoietin (NEPO) have been evaluated in the valproic acid (VPA) rat model of autism." | 8.31 | The effects of postnatal erythropoietin and nano-erythropoietin on behavioral alterations by mediating K-Cl co-transporter 2 in the valproic acid-induced rat model of autism. ( Basiri, M; Darvishzadeh-Mahani, F; Haratizadeh, S; Nozari, M; Ranjbar, M, 2023) |
| "Autism spectrum disorders are complex behavioral disorders that can be caused by exposure to valproic acid (VPA) during pregnancy." | 8.31 | Effects of varied‑intensity endurance exercise training on oxidative and antioxidant factors in the liver of rats with valproic acid‑induced autism. ( Aminzadeh, A; Bashiri, H; Heidari, M; Mirzavandi, F; Moslemizadeh, A; Parizi, AS; Pouya, F; Sabet, N, 2023) |
| "Risperidone is the first antipsychotic to be approved by Food and Drug Administration (FDA) for treating autism spectrum disorder (ASD)." | 8.31 | The comparative effectiveness of metformin and risperidone in a rat model of valproic acid-induced autism, Potential role for enhanced autophagy. ( Ashour, RH; Atia, AA; Rahman, KM; Ramadan, NM; Zaki, MM, 2023) |
| "N-acetylcysteine (NAC) has been reported to improve social interaction behavior, irritability, self-injury, and anxiety-like behavior in autism." | 8.31 | N-acetylcysteine improves autism-like behavior by recovering autophagic deficiency and decreasing Notch-1/Hes-1 pathway activity. ( Deng, YN; He, XL; Li, YF; Wang, LJ; Wang, T; Zhang, YH, 2023) |
| " Valproic acid (VPA) exposure during pregnancy causes autistic-like traits in offspring." | 8.31 | The antipsychotic olanzapine reduces memory deficits and neuronal abnormalities in a male rat model of Autism. ( Aguilar-Hernandez, L; Bringas, ME; Flores, G; Garcés-Ramírez, L; Lima-Castañeda, LÁ; Morales-Medina, JC, 2023) |
| "Prenatal exposure to valproic acid (VPA) may enhance the risk of autism spectrum disorder (ASD) in children." | 8.31 | Prangos ferulacea (L.) ameliorates behavioral alterations, hippocampal oxidative stress markers, and apoptotic deficits in a rat model of autism induced by valproic acid. ( Aldaghi, MR; Raise-Abdullahi, P; Saadat, M; Sameni, HR; Taherian, AA; Vafaei, AA, 2023) |
| "This study aims to understand the relationship between fecal metabolites and gut microbiota in an adolescent valproic acid-induced rat autism model (VPA-exposed offspring)." | 8.12 | Correlation among gut microbiota, fecal metabolites and autism-like behavior in an adolescent valproic acid-induced rat autism model. ( Gu, Y; Han, Y; Qin, J; Ren, S; Wang, X; Zhang, B; Zhang, S; Zhao, Y, 2022) |
| "Valproic acid (VPA) exposure as an environmental factor that confers risk of autism spectrum disorder (ASD), its functional mechanisms in the human brain remain unclear since relevant studies are currently restricted to two-dimensional cell cultures and animal models." | 8.12 | Human forebrain organoids reveal connections between valproic acid exposure and autism risk. ( Chen, C; Jiao, C; Liu, C; Meng, Q; Tang, B; Wang, X; Xu, S; Zhang, W, 2022) |
| "In this study, we performed 16S rRNA gene sequencing and untargeted metabolomics in parallel on fecal samples from a valproic acid (VPA)-induced rat model of autism (VPA rats)." | 8.02 | Sex-specific differences in the gut microbiota and fecal metabolites in an adolescent valproic acid-induced rat autism model. ( Cui, YN; Gu, YY; Han, Y; Liang, JJ; Qin, J; Zhang, B; Zhang, SB; Zhang, Y, 2021) |
| " The present work aimed to detect changes in the AVP numbers and level in a valproic acid (VPA)-induced rat model of autism and the underlying mechanism of its pathogenesis." | 8.02 | Postnatal AVP treatments prevent social deficit in adolescence of valproic acid-induced rat autism model. ( Bai, SZ; Dai, YC; Han, JS; Han, SP; Hu, Y; Lan, XY; Wu, J; Zhang, HF; Zhang, R, 2021) |
| "This study was performed to evaluate the effects of prenatal exposure to pregabalin (PGB) on behavioral changes of rat offspring in an animal model of valproic acid (VPA)-induced autism-like symptoms." | 7.96 | Prenatal pregabalin is associated with sex-dependent alterations in some behavioral parameters in valproic acid-induced autism in rat offspring. ( Bashiri, H; Moslemizadeh, A; Sepehri, G; Shamsi Meymandi, M; Vakili Shahrbabaki, S, 2020) |
| "In previous studies we produced autism like behavioral changes in mice by Valproic acid (VPA) with significant differences between genders." | 7.91 | Gender Related Changes in Gene Expression Induced by Valproic Acid in A Mouse Model of Autism and the Correction by S-adenosyl Methionine. Does It Explain the Gender Differences in Autistic Like Behavior? ( Ergaz, Z; Ornoy, A; Szyf, M; Turgeman, G; Weinstein-Fudim, L; Yanai, J, 2019) |
| " The aim of this study was to assess the behavioral effects of acute inhalation of subanesthetic concentrations of Xe and to study the outcomes of Xe exposure in valproic acid (VPA)-induced rodent model of autism." | 7.91 | Beneficial effects of xenon inhalation on behavioral changes in a valproic acid-induced model of autism in rats. ( Bogin, VI; Dobrovolsky, AP; Dubynin, VA; Gedzun, VR; Ichim, TE; Ma, D; Malyshev, AV; Sukhanova, IA, 2019) |
| " Valproic acid (VPA) is an anticonvulsant drug in both human and rodents with teratogenic effects during pregnancy." | 7.91 | Benefits of Fenofibrate in prenatal valproic acid-induced autism spectrum disorder related phenotype in rats. ( Mirza, R; Sharma, B, 2019) |
| "To establish an improved mouse model of valproic acid (VPA)-induced autism that better mimics human autism." | 7.91 | [Improvement of a mouse model of valproic acid-induced autism]. ( Chen, D; Hu, Y; Li, Y; Wang, S; Zheng, W, 2019) |
| "We utilized a valproic acid (VPA) -induced rat model of autism to evaluate the levels of S1P and the expression of sphingosine kinase (SphK), a key enzyme for S1P production, in serum and hippocampal tissue." | 7.88 | Modulation of sphingosine 1-phosphate (S1P) attenuates spatial learning and memory impairments in the valproic acid rat model of autism. ( Cao, Y; Gao, J; Hao, Y; Sun, C; Wang, J; Wu, H; Wu, L; Xia, W; Zhang, Q, 2018) |
| "Prenatal exposure to valproic acid (VPA) induces behavioral disorders and enhancement of oxido-inflammatory stress in Autism Spectrum Disorders (ASDs)." | 7.88 | Hesperetin and it nanocrystals ameliorate social behavior deficits and oxido-inflammatory stress in rat model of autism. ( Hajizadeh Moghaddam, A; Khalaj, R; Zare, M, 2018) |
| "Considering the potential role of lymphocytes in the pathophysiology of autism spectrum disorder (ASD), we aimed to evaluate possible alterations of T cell pools in the lymphoid organs of an animal model of autism induced by valproic acid (VPA)." | 7.88 | Reduced CD4 T Lymphocytes in Lymph Nodes of the Mouse Model of Autism Induced by Valproic Acid. ( Bambini-Junior, V; Baronio, D; Bauer-Negrini, G; Castro, K; Della-Flora Nunes, G; Gottfried, C; Mendes-da-Cruz, DA; Riesgo, R; Savino, W, 2018) |
| ") on sociability, social novelty, anxiety, and aggressive/repetitive behavior in male Tuck-Ordinary (TO) mice with ASD-like behaviors induced by prenatal exposure to valproic acid (VPA, 500 mg/kg, i." | 7.88 | The histamine H3R antagonist DL77 attenuates autistic behaviors in a prenatal valproic acid-induced mouse model of autism. ( Al-Houqani, M; Azimullah, S; Eissa, N; Jalal, FY; Jayaprakash, P; Kieć-Kononowicz, K; Ojha, SK; Sadek, B; Łażewska, D, 2018) |
| "We have investigated the species richness and microbial composition in a valproic acid (VPA)-induced rat model autism." | 7.88 | The valproic acid rat model of autism presents with gut bacterial dysbiosis similar to that in human autism. ( Horton-Sparks, K; Hull, V; Li, RW; Liu, F; Martínez-Cerdeño, V, 2018) |
| "The aim was to identify the effects of early vitamin D supplementation on autism-like behaviors (ASD) induced by valproic acid (VPA, an anti-convulsant and a mood stabilizer) in rats." | 7.85 | Behavioral improvements in a valproic acid rat model of autism following vitamin D supplementation. ( Du, L; Duan, Z; Li, F; Zhao, G, 2017) |
| "The study was performed using a rodent model of autism by exposing rat fetuses to valproic acid (VPA) on the 12." | 7.85 | Postnatal treatment using curcumin supplements to amend the damage in VPA-induced rodent models of autism. ( Al-Askar, M; Al-Ayadhi, L; Bhat, RS; El-Ansary, A; Selim, M, 2017) |
| "N-acetylcysteine (NAC) is widely used as an antioxidant, and previous studies have suggested that it may have potential as an alternative therapeutic strategy for the treatment of patients with autism." | 7.85 | N-acetylcysteine ameliorates repetitive/stereotypic behavior due to its antioxidant properties without activation of the canonical Wnt pathway in a valproic acid-induced rat model of autism. ( Cui, W; Wen, X; Zhai, Q; Zhang, T; Zhang, Y, 2017) |
| "Recent studies have reported that oxytocin ameliorates behavioral abnormalities in both animal models and individuals with autism spectrum disorders (ASD)." | 7.85 | Oxytocin attenuates deficits in social interaction but not recognition memory in a prenatal valproic acid-induced mouse model of autism. ( Ago, Y; Hara, Y; Hasebe, S; Hashimoto, H; Higuchi, M; Matsuda, T; Nakazawa, T; Takuma, K, 2017) |
| "The present study was undertaken to elucidate the effect of alpha-linolenic acid (ALA, 18:3, ω-3) and gamma-linolenic acid (GLA, 18:3, ω-6) on experimental autism features induced by early prenatal exposure to valproic acid (VPA) in albino wistar pups." | 7.85 | Comparative efficacy of alpha-linolenic acid and gamma-linolenic acid to attenuate valproic acid-induced autism-like features. ( Ansari, MN; Devi, U; Gautam, S; Kaithwas, G; Prakash, A; Rawat, JK; Roy, S; Saeedan, AS; Saraf, SA; Singh, M; Tiwari, V; Yadav, RK; Yadav, S, 2017) |
| "Prenatal exposure to valproic acid (VPA) in rat offspring is capable of inducing experimental autism with neurobehavioral aberrations." | 7.83 | Neuroprotective effects of docosahexaenoic acid on hippocampal cell death and learning and memory impairments in a valproic acid-induced rat autism model. ( Cao, Y; Gao, J; Liang, S; Sun, H; Wang, H; Wang, X; Wang, Y; Wu, L; Yang, F; Zhang, F, 2016) |
| "Rodents exposed prenatally to valproic acid (VPA) show autism-related behavioral abnormalities." | 7.83 | Improvement by methylphenidate and atomoxetine of social interaction deficits and recognition memory impairment in a mouse model of valproic acid-induced autism. ( Ago, Y; Hara, Y; Hasebe, S; Hashimoto, H; Katashiba, K; Matsuda, T; Onaka, Y; Takano, E; Takuma, K; Taruta, A, 2016) |
| "Exposure to valproic acid (VPA) during pregnancy has been linked with increased incidence of autism, and has repeatedly been demonstrated as a useful autism mouse model." | 7.83 | Early Behavioral Abnormalities and Perinatal Alterations of PTEN/AKT Pathway in Valproic Acid Autism Model Mice. ( Ahn, S; Kim, HS; Lee, K; Mahmood, U; Yang, EJ, 2016) |
| "Autism is a neurodevelopmental disorder, and embryonic exposure to valproic acid (VPA) in rodents is the most frequently studied environmentally triggered autism models." | 7.83 | Validation of reference genes for quantitative real-time PCR in valproic acid rat models of autism. ( Ren, J; Tian, Y; Wang, P; Wei, Z; Zhang, J; Zhang, X; Zhou, J, 2016) |
| "Stiripentol is an antiepileptic drug (AED) approved by the European Medicines Agency for the treatment of Dravet Syndrome (DS) as adjunct treatment with valproate and clobazam." | 7.81 | Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy. ( Specchio, N; Trivisano, M; Vigevano, F, 2015) |
| "Components of the mTOR pathway were assayed by Western blotting in postmortem fusiform gyrus samples from 11 subjects with idiopathic autism and 13 controls and in valproic acid versus saline-exposed rat neocortex." | 7.81 | Decreased mTOR signaling pathway in human idiopathic autism and in rats exposed to valproic acid. ( Ahn, Y; Fahnestock, M; Michalski, B; Nicolini, C; Rho, JM, 2015) |
| "Valproic acid (VPA) mouse model of autism spectrum disorder (ASD) has been characterized mostly by impaired ultrasonic vocalization, poor sociability and increased repetitive self-grooming behavior." | 7.81 | Characterization of in utero valproic acid mouse model of autism by local field potential in the hippocampus and the olfactory bulb. ( Bumrungsri, S; Chatpun, S; Cheaha, D; Kumarnsit, E, 2015) |
| "Human fetal exposure to valproic acid (VPA), a widely-used anti-epileptic and mood-stabilizing drug, leads to an increased incidence of behavioral and intellectual impairments including autism; VPA administration to pregnant rats and mice at gestational days 12." | 7.80 | Increased BDNF expression in fetal brain in the valproic acid model of autism. ( Almeida, LE; Krueger, BK; Roby, CD, 2014) |
| "We report that the oxytocin-mediated neuroprotective γ-aminobutyric acid (GABA) excitatory-inhibitory shift during delivery is abolished in the valproate and fragile X rodent models of autism." | 7.80 | Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring. ( Ben-Ari, Y; Brouchoud, C; Burnashev, N; Chazal, G; Eftekhari, S; Ferrari, DC; Khalilov, I; Lemonnier, E; Lozovaya, N; Nardou, R; Shahrokhi, A; Tsintsadze, T; Tsintsadze, V; Tyzio, R, 2014) |
| "Post natal exposure to VPA (valproic acid) in mice induces behavioral deficits, abnormal sensitivity to sensory stimuli and self-injurious behavior, observed in autism." | 7.80 | Ameliorating effect of piperine on behavioral abnormalities and oxidative markers in sodium valproate induced autism in BALB/C mice. ( Kameshwari, JS; Pragnya, B; Veeresh, B, 2014) |
| "We recently showed that prenatal exposure to valproic acid (VPA) in mice causes autism-like behavioral abnormalities, including social interaction deficits, anxiety-like behavior and spatial learning disability, in male offspring." | 7.80 | Chronic treatment with valproic acid or sodium butyrate attenuates novel object recognition deficits and hippocampal dendritic spine loss in a mouse model of autism. ( Ago, Y; Hara, Y; Hashimoto, H; Hayata-Takano, A; Kataoka, S; Kawanai, T; Maeda, Y; Matsuda, T; Takano, E; Takuma, K; Watanabe, R, 2014) |
| "Autism spectrum disorders (ASD) involve a complex interplay of both genetic and environmental risk factors, such as prenatal exposure to valproic acid (VPA)." | 7.80 | Resveratrol prevents social deficits in animal model of autism induced by valproic acid. ( Bambini-Junior, V; Della Flora Nunes, G; Fontes-Dutra, M; Gottfried, C; Michels, M; Mueller de Melo, G; Nogueira Freire, V; Riesgo, R; Zanatta, G, 2014) |
| "The aim of this work is to evaluate the impact of butyl paraben (BP) in brain of the pups developed for mothers administered BP from early pregnancy till weaning and its effect on studying the behavior, brain neurotransmitters and brain derived neurotrophic factor BDNF via comparing the results with valproic acid (VA) autistic-rat model preparing by a single oral injection dose of VA (800 mg/kg b." | 7.79 | Combined prenatal and postnatal butyl paraben exposure produces autism-like symptoms in offspring: comparison with valproic acid autistic model. ( Ali, EH; Elgoly, AH, 2013) |
| "Maternal use of valproic acid (VPA) during pregnancy has been implicated in the aetiology of autism spectrum disorders in children, and rodents prenatally exposed to VPA showed behavioural alterations similar to those observed in humans with autism." | 7.79 | Autism-like behaviours with transient histone hyperacetylation in mice treated prenatally with valproic acid. ( Ago, Y; Hara, Y; Kataoka, S; Maeda, Y; Matsuda, T; Takuma, K, 2013) |
| "Valproic acid (VPA) is an anticonvulsant and mood stabilizer that, when used during the gestational period, increases the risk of ASD in the offspring." | 6.58 | Neuroimmune Alterations in Autism: A Translational Analysis Focusing on the Animal Model of Autism Induced by Prenatal Exposure to Valproic Acid. ( Bambini-Junior, V; Deckmann, I; Fontes-Dutra, M; Gottfried, C; Schwingel, GB, 2018) |
| "Valproic acid (VPA) is a known human teratogen." | 6.45 | Valproic acid in pregnancy: how much are we endangering the embryo and fetus? ( Ornoy, A, 2009) |
| "Valproic acid (VPA) is an effective drug, which is preferred for the treatments of epilepsy and various kinds of seizures." | 6.44 | The effects of valproic acid neurotoxicity on aggressive behavior in zebrafish autism model. ( Feng, T; Li, X; Lu, W, 2024) |
| "When treatment with valproic acid is the most appropriate treatment to achieve optimal seizure control, a number of measures can be implemented to minimise risk to the fetus." | 6.43 | Valproic acid in epilepsy : pregnancy-related issues. ( Genton, P; Semah, F; Trinka, E, 2006) |
| "Thymol is a bioactive monoterpene isolated from Thymus vulgaris that has anti-inflammatory properties and is helpful in neurodevelopmental disorders." | 5.91 | Thymol improves autism-like behaviour in VPA-induced ASD rats through the Pin1/p38 MAPK pathway. ( Chen, J; Li, Y; Lv, M; Tang, B; Wang, F; Xiong, Y; Zhang, H, 2023) |
| " The repetitive behaviors were ameliorated relatively in VPA groups with NEPO2000 treatment, and astrogliosis was reduced even when VPA rats were treated with a lower dosage of NEPO." | 5.91 | Astrocyte responses to postnatal erythropoietin and nano-erythropoietin treatments in a valproic acid-induced animal model of autism. ( Basiri, M; Haratizadeh, S; Nozari, M; Ranjbar, M, 2023) |
| "Many studies show that the number of cognitive impairmentscan be reduced by antagonists of the histamine H3 receptor (H3R)." | 5.91 | Amelioration of cognition impairments in the valproic acid-induced animal model of autism by ciproxifan, a histamine H3-receptor antagonist. ( Esmaeilpour, K; Sepehri, G; Sheibani, V; Shekari, MA; Taheri, F, 2023) |
| "Valproic acid (VPA) is a well-known anti-epileptic drug, but its prenatal exposure to animals causes social impairment, neurotransmitters imbalance, and neuroinflammation with ASD-like phenotypes." | 5.91 | Syringic acid alleviates valproic acid induced autism via activation of p38 mitogen-activated protein kinase: Possible molecular approach. ( Mallan, S; Singh, S, 2023) |
| "The mouse model of autism induced by prenatal exposure to valproic acid (VPA) was used to assess the therapeutic potential of STX209 on autism‑like behaviour in the present study." | 5.72 | The GABAB receptor agonist STX209 reverses the autism‑like behaviour in an animal model of autism induced by prenatal exposure to valproic acid. ( Chang, H; Ding, J; Gao, C; He, M; Jiang, S; Li, W; Sun, T; Sun, Y; Wang, F; Wang, Y; Xiao, L; Zhu, C, 2022) |
| " Pregnant C57BL/6 J mice were intraperitoneally injected with a dosage of 500 mg/kg valproic acid (VPA) on embryonic day 10." | 5.72 | Size anomaly and alteration of GABAergic enzymes expressions in cerebellum of a valproic acid mouse model of autism. ( Kwan, KM; Ma, SY, 2022) |
| "Autism spectrum disorder is a neurodevelopmental disorder characterized by sensory abnormalities, social skills impairment and cognitive deficits." | 5.72 | Alterations in the intrinsic discharge activity of CA1 pyramidal neurons associated with possible changes in the NADPH diaphorase activity in a rat model of autism induced by prenatal exposure to valproic acid. ( Behzadi, G; Borjkhani, M; Davoudi, S; Hajisoltani, R; Hosseinmardi, N; Janahmadi, M; Karimi, SA; Khatibi, VA; Rahdar, M, 2022) |
| "Previous studies have indicated that autism-like behavioral phenotypes detected in F1 VPA mice transgenetically appear in F2 and F3 generations." | 5.72 | Early-onset of social communication and locomotion activity in F2 pups of a valproic acid-induced mouse model of autism. ( Fu, P; Furuhara, K; Higashida, H; Minami, K; Mizutani, R; Tsuji, C; Tsuji, T; Yokoyama, S; Zhong, J, 2022) |
| "Melatonin is an endogenous hormone and can restore gut microbial dysbiosis under various disease conditions." | 5.72 | Rescue of social deficits by early-life melatonin supplementation through modulation of gut microbiota in a murine model of autism. ( Cui, Y; Li, XG; Liu, W; Liu, X; Qiu, B; Wang, X; Xiang, G; Yu, M; Zhang, D; Zhang, Y, 2022) |
| "Despite the increasing prevalence of autism spectrum disorder (ASD), there is still a deficiency in understanding its exact pathophysiology and treatment, therefore validation of translational ASD animal model is warranted." | 5.62 | Validation of prenatal versus postnatal valproic acid rat models of autism: A behavioral and neurobiological study. ( Abdelraouf, SM; Aboul-Fotouh, S; Abuelezz, SA; Ahmed, AI; Bahaa, N; Elnahas, EM; Hassan, GA; Ibrahim, EA; Mohamad, MI; Nabil, MM, 2021) |
| "These results showed that VAD in autism might result in cerebellar impairments and be a factor aggravating a subtype of ASD with motor comorbidities." | 5.62 | Vitamin A supplementation ameliorates motor incoordination via modulating RORα in the cerebellum in a valproic acid-treated rat autism model with vitamin A deficiency. ( Cheng, B; Hou, N; Li, L; Li, T; Liu, H; Wang, S; Wu, Q; Yang, T, 2021) |
| "Suramin treatment did not affect VPA-induced upregulation of P2X4 and P2Y2 receptor expression in the hippocampus, and P2X4 receptor expression in the medial prefrontal cortex, but normalized an increased level of interleukin 6 (IL-6)." | 5.56 | Effects of single-dose antipurinergic therapy on behavioral and molecular alterations in the valproic acid-induced animal model of autism. ( Bambini-Junior, V; Bauer-Negrini, G; Brum Schwingel, G; Carello-Collar, G; Castillo, ARG; Corrêa-Velloso, J; Deckmann, I; Fontes-Dutra, M; Gonçalves, MCB; Gottfried, C; Hirsch, MM; Körbes-Rockenbach, M; Naaldijk, Y; Rabelo, B; Santos-Terra, J; Schneider, T; Staevie, GZ; Ulrich, H, 2020) |
| "Quercetin (50 mg/kg) was administered orally to the animals from gestational days 6." | 5.56 | Quercetin prevents alterations of behavioral parameters, delta-aminolevulinic dehydratase activity, and oxidative damage in brain of rats in a prenatal model of autism. ( Baldissarelli, J; de Mattos, BDS; de Souza, AA; Gamaro, GD; Pedra, NS; Soares, MSP; Spanevello, RM; Spohr, L; Stefanello, FM; Teixeira, FC, 2020) |
| "The manifestations of autism spectrum disorder (ASD) are highly heterogeneous." | 5.56 | Vitamin A deficiency exacerbates autism-like behaviors and abnormalities of the enteric nervous system in a valproic acid-induced rat model of autism. ( Chen, J; Cheng, B; Li, T; Liu, H; Wang, S; Wu, Q; Yang, T; Zhang, X; Zhu, J, 2020) |
| "The social motivational theory of autism spectrum disorder (ASD) focuses on social anhedonia as key causal feature of the impaired peer relationships that characterize ASD patients." | 5.56 | Targeting PPARα in the rat valproic acid model of autism: focus on social motivational impairment and sex-related differences. ( Braccagni, G; De Montis, MG; Gambarana, C; Guzzi, F; Parenti, M; Scheggi, S, 2020) |
| "Autism is characterized by numerous behavioral impairments, such as in communication, socialization and cognition." | 5.48 | Zinc as a therapy in a rat model of autism prenatally induced by valproic acid. ( Bernardi, MM; Cezar, LC; da Fonseca, CCN; de Lima, APN; Felicio, LF; Kirsten, TB, 2018) |
| "Rats of the VPA model of autism showed reduced total reciprocal social interaction, prevented by prenatal treatment with resveratrol (RSV)." | 5.48 | Behavioral alterations in autism model induced by valproic acid and translational analysis of circulating microRNA. ( Bambini-Junior, V; Bauer-Negrini, G; Deckmann, I; Della-Flora Nunes, G; Fontes-Dutra, M; Gottfried, C; Hirsch, MM; Margis, R; Nunes, W; Rabelo, B; Riesgo, R, 2018) |
| "The etiology of autism remains unknown and its molecular basis is not yet well understood." | 5.48 | Social behavior, neuroimmune markers and glutamic acid decarboxylase levels in a rat model of valproic acid-induced autism. ( Imai, M; Lwin, TT; Mar, O; Nway, NC; Watanabe, H; Win-Shwe, TT, 2018) |
| "The novel therapeutic strategy against autism is essential due to the limited therapeutic efficacy." | 5.46 | Laser Acupuncture at HT7 Improves the Cerebellar Disorders in Valproic Acid-Rat Model of Autism. ( Khongrum, J; Wattanathorn, J, 2017) |
| "Valproic acid (600 mg/kg) was administered intraperitoneally to the pregnant mice on gestational day 12." | 5.42 | Astaxanthin improves behavioral disorder and oxidative stress in prenatal valproic acid-induced mice model of autism. ( Al-Amin, MM; Khan, FR; Mahmud Reza, H; Rahman, MM; Zaman, F, 2015) |
| "The therapeutic strategy against autism, a severe neurological development disorder, is one of the challenges of this decade." | 5.42 | Laser Acupuncture Improves Behavioral Disorders and Brain Oxidative Stress Status in the Valproic Acid Rat Model of Autism. ( Khongrum, J; Wattanathorn, J, 2015) |
| "Previously, autism spectrum disorder (ASD) has been identified mainly by social communication deficits and behavioral symptoms." | 5.42 | Alteration of spontaneous spectral powers and coherences of local field potential in prenatal valproic acid mouse model of autism. ( Cheaha, D; Kumarnsit, E, 2015) |
| "Autism is characterized by behavioral impairments in three main domains: social interaction; language, communication and imaginative play; and the range of interests and activities." | 5.39 | Increased hippocampal cell density and enhanced spatial memory in the valproic acid rat model of autism. ( Edalatmanesh, MA; Moghadas, M; Nikfarjam, H; Vafaee, F, 2013) |
| "In order to establish the etiology of autism with facial palsy, research into developmental abnormalities of the peripheral facial nerves is necessary." | 5.37 | Morphological abnormalities of embryonic cranial nerves after in utero exposure to valproic acid: implications for the pathogenesis of autism with multiple developmental anomalies. ( Imura, Y; Narita, M; Narita, N; Oyabu, A; Tashiro, Y; Uchida, A, 2011) |
| "Autism is a behaviorally characterized disorder with impairments in social interactions, as well as stereotyped, repetitive patterns of behaviors and interests." | 5.36 | Nonexploratory movement and behavioral alterations in a thalidomide or valproic acid-induced autism model rat. ( Imura, Y; Kamada, N; Narita, M; Narita, N; Oyabu, A; Tano, K; Uchida, A; Yokoyama, T, 2010) |
| "Autism is a severe behavioral disorder characterized by pervasive impairments in social interactions, deficits in verbal and non-verbal communication, and stereotyped behaviors, with a four times higher incidence in boys than in girls." | 5.35 | Gender-specific behavioral and immunological alterations in an animal model of autism induced by prenatal exposure to valproic acid. ( Basta-Kaim, A; Budziszewska, B; Kubera, M; Przewłocki, R; Roman, A; Schneider, K; Schneider, T, 2008) |
| "Recently, a new rodent model of autism was created by exposure of rat fetuses to valproic acid (VPA) on the 12." | 5.33 | Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. ( Przewłocki, R; Schneider, T, 2005) |
| "Morphologic abnormalities found in autism (e." | 5.31 | Increased monoamine concentration in the brain and blood of fetal thalidomide- and valproic acid-exposed rat: putative animal models for autism. ( Kato, M; Miyazaki, K; Narita, M; Narita, N; Okado, N; Tazoe, M, 2002) |
| "Valproic acid (VPA) induced rodent model of autism is a widely accepted and extensively used rodent model to investigate the pharmacotherapy against autism." | 5.22 | Critical Evaluation of Valproic Acid-Induced Rodent Models of Autism: Current and Future Perspectives. ( Chopra, M; Mehra, S; Seth, E; Ul Ahsan, A, 2022) |
| "The objectives of this study were to determine whether autistic children taking levetiracetam (1) showed improvement in the areas of aggression, impulsivity, hyperkinesis, and mood instability, and (2) showed a nootropic response." | 5.10 | Levetiracetam in autistic children: an open-label study. ( Rugino, TA; Samsock, TC, 2002) |
| " Oxcarbazepine and lamotrigine were associated with increased occurrence of autism." | 4.95 | Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis. ( Cogo, E; D'Souza, J; Finkelstein, Y; Hemmelgarn, BR; Hutton, B; Kealey, R; MacDonald, H; Reynen, E; Rios, P; Soobiah, C; Straus, SE; Thavorn, K; Tricco, AC; Veroniki, AA; Yazdi, F, 2017) |
| "In this study, based on the excitatory/inhibitory imbalance theory of autism, the time window of GABA switch, the role of K-Cl co-transporter 2 (KCC2) in adjustment GABA switch, and brain permeability to erythropoietin (EPO), the effects of postnatal -EPO and- nano- erythropoietin (NEPO) have been evaluated in the valproic acid (VPA) rat model of autism." | 4.31 | The effects of postnatal erythropoietin and nano-erythropoietin on behavioral alterations by mediating K-Cl co-transporter 2 in the valproic acid-induced rat model of autism. ( Basiri, M; Darvishzadeh-Mahani, F; Haratizadeh, S; Nozari, M; Ranjbar, M, 2023) |
| "The prenatal valproic acid (VPA) model was used to induce autism-like behaviors in offspring rats." | 4.31 | Inhalation of Cananga odorata essential oil relieves anxiety behaviors in autism-like rats via regulation of serotonin and dopamine metabolism. ( Wang, ST; Yao, L; Zhang, N, 2023) |
| "Microglial dysfunction has been reported in the valproic acid (VPA)-induced autism spectrum disorder (ASD) rat models." | 4.31 | Prenatally VPA exposure is likely to cause autistic-like behavior in the rats offspring via TREM2 down-regulation to affect the microglial activation and synapse alterations. ( Chen, J; Hu, C; Li, T; Luo, L; Wei, H; Wu, Q; Yang, T; Yuan, B, 2023) |
| "Autism spectrum disorder is a developmental disorder that can affect sensory-motor behaviors in the valproic acid (Val) rodent model of autism." | 4.31 | Alteration in social interaction and tactile discrimination of juvenile autistic-like rats following tactile stimulation and whisker deprivation. ( Afarinesh, MR; Ahmadi, BBM; Jafaripour, L; Sheibani, V, 2023) |
| "Autism spectrum disorders are complex behavioral disorders that can be caused by exposure to valproic acid (VPA) during pregnancy." | 4.31 | Effects of varied‑intensity endurance exercise training on oxidative and antioxidant factors in the liver of rats with valproic acid‑induced autism. ( Aminzadeh, A; Bashiri, H; Heidari, M; Mirzavandi, F; Moslemizadeh, A; Parizi, AS; Pouya, F; Sabet, N, 2023) |
| "Risperidone is the first antipsychotic to be approved by Food and Drug Administration (FDA) for treating autism spectrum disorder (ASD)." | 4.31 | The comparative effectiveness of metformin and risperidone in a rat model of valproic acid-induced autism, Potential role for enhanced autophagy. ( Ashour, RH; Atia, AA; Rahman, KM; Ramadan, NM; Zaki, MM, 2023) |
| "N-acetylcysteine (NAC) has been reported to improve social interaction behavior, irritability, self-injury, and anxiety-like behavior in autism." | 4.31 | N-acetylcysteine improves autism-like behavior by recovering autophagic deficiency and decreasing Notch-1/Hes-1 pathway activity. ( Deng, YN; He, XL; Li, YF; Wang, LJ; Wang, T; Zhang, YH, 2023) |
| " Valproic acid (VPA) exposure during pregnancy causes autistic-like traits in offspring." | 4.31 | The antipsychotic olanzapine reduces memory deficits and neuronal abnormalities in a male rat model of Autism. ( Aguilar-Hernandez, L; Bringas, ME; Flores, G; Garcés-Ramírez, L; Lima-Castañeda, LÁ; Morales-Medina, JC, 2023) |
| "Prenatal exposure to valproic acid (VPA) may enhance the risk of autism spectrum disorder (ASD) in children." | 4.31 | Prangos ferulacea (L.) ameliorates behavioral alterations, hippocampal oxidative stress markers, and apoptotic deficits in a rat model of autism induced by valproic acid. ( Aldaghi, MR; Raise-Abdullahi, P; Saadat, M; Sameni, HR; Taherian, AA; Vafaei, AA, 2023) |
| "This study aims to understand the relationship between fecal metabolites and gut microbiota in an adolescent valproic acid-induced rat autism model (VPA-exposed offspring)." | 4.12 | Correlation among gut microbiota, fecal metabolites and autism-like behavior in an adolescent valproic acid-induced rat autism model. ( Gu, Y; Han, Y; Qin, J; Ren, S; Wang, X; Zhang, B; Zhang, S; Zhao, Y, 2022) |
| "Valproic acid (VPA) exposure as an environmental factor that confers risk of autism spectrum disorder (ASD), its functional mechanisms in the human brain remain unclear since relevant studies are currently restricted to two-dimensional cell cultures and animal models." | 4.12 | Human forebrain organoids reveal connections between valproic acid exposure and autism risk. ( Chen, C; Jiao, C; Liu, C; Meng, Q; Tang, B; Wang, X; Xu, S; Zhang, W, 2022) |
| "Maternal exposure to anti-epileptic drug Valproic acid (VPA) during pregnancy increases the risk for the development of autism spectrum disorders (ASD)." | 4.12 | Prenatal exposure to valproic acid alters Reelin, NGF expressing neuron architecture and impairs social interaction in their autistic-like phenotype male offspring. ( Rajan, KE; Sivasangari, K, 2022) |
| "In this study, we performed 16S rRNA gene sequencing and untargeted metabolomics in parallel on fecal samples from a valproic acid (VPA)-induced rat model of autism (VPA rats)." | 4.02 | Sex-specific differences in the gut microbiota and fecal metabolites in an adolescent valproic acid-induced rat autism model. ( Cui, YN; Gu, YY; Han, Y; Liang, JJ; Qin, J; Zhang, B; Zhang, SB; Zhang, Y, 2021) |
| " The present work aimed to detect changes in the AVP numbers and level in a valproic acid (VPA)-induced rat model of autism and the underlying mechanism of its pathogenesis." | 4.02 | Postnatal AVP treatments prevent social deficit in adolescence of valproic acid-induced rat autism model. ( Bai, SZ; Dai, YC; Han, JS; Han, SP; Hu, Y; Lan, XY; Wu, J; Zhang, HF; Zhang, R, 2021) |
| " For the first time, we assessed the synthesis of 5-hydroxytryptamine (5HT) and the metabolic capacity of the 5HT system in the peripheral and central nervous systems (PNS and CNS, respectively) based on tryptophan metabolism based on VPA-induced autism model." | 4.02 | Daily intake of Lactobacillus alleviates autistic-like behaviors by ameliorating the 5-hydroxytryptamine metabolic disorder in VPA-treated rats during weaning and sexual maturation. ( Chen, W; Kong, Q; Li, X; Tian, P; Wang, B; Wang, G; Zhang, H; Zhao, J, 2021) |
| " The present work detected the effects of pregnancy supplementation with folic acid (FA) at different doses on rat models of ASD induced by prenatal exposure to valproic acid (VPA), an anti-epileptic increasing the risk of ASD when administered during pregnancy." | 4.02 | Maternal folic acid supplementation prevents autistic behaviors in a rat model induced by prenatal exposure to valproic acid. ( Cheng, Q; Di, Y; Fan, J; Kang, M; Lan, J; Li, J; Li, Z; Ren, W; Tian, Y; Wei, C; Zhai, C; Zheng, Q, 2021) |
| "This study was performed to evaluate the effects of prenatal exposure to pregabalin (PGB) on behavioral changes of rat offspring in an animal model of valproic acid (VPA)-induced autism-like symptoms." | 3.96 | Prenatal pregabalin is associated with sex-dependent alterations in some behavioral parameters in valproic acid-induced autism in rat offspring. ( Bashiri, H; Moslemizadeh, A; Sepehri, G; Shamsi Meymandi, M; Vakili Shahrbabaki, S, 2020) |
| "In previous studies we produced autism like behavioral changes in mice by Valproic acid (VPA) with significant differences between genders." | 3.91 | Gender Related Changes in Gene Expression Induced by Valproic Acid in A Mouse Model of Autism and the Correction by S-adenosyl Methionine. Does It Explain the Gender Differences in Autistic Like Behavior? ( Ergaz, Z; Ornoy, A; Szyf, M; Turgeman, G; Weinstein-Fudim, L; Yanai, J, 2019) |
| " The aim of this study was to assess the behavioral effects of acute inhalation of subanesthetic concentrations of Xe and to study the outcomes of Xe exposure in valproic acid (VPA)-induced rodent model of autism." | 3.91 | Beneficial effects of xenon inhalation on behavioral changes in a valproic acid-induced model of autism in rats. ( Bogin, VI; Dobrovolsky, AP; Dubynin, VA; Gedzun, VR; Ichim, TE; Ma, D; Malyshev, AV; Sukhanova, IA, 2019) |
| " Valproic acid (VPA) is an anticonvulsant drug in both human and rodents with teratogenic effects during pregnancy." | 3.91 | Benefits of Fenofibrate in prenatal valproic acid-induced autism spectrum disorder related phenotype in rats. ( Mirza, R; Sharma, B, 2019) |
| "To establish an improved mouse model of valproic acid (VPA)-induced autism that better mimics human autism." | 3.91 | [Improvement of a mouse model of valproic acid-induced autism]. ( Chen, D; Hu, Y; Li, Y; Wang, S; Zheng, W, 2019) |
| "Prenatal exposure to the antiepileptic and mood stabilizer valproic acid (VPA) is an environmental risk factor for autism spectrum disorders (ASD), although recent epidemiological studies show that the public awareness of this association is still limited." | 3.88 | Impaired repair of DNA damage is associated with autistic-like traits in rats prenatally exposed to valproic acid. ( Ascenzi, P; Campolongo, P; di Masi, A; Leboffe, L; Manduca, A; Melancia, F; Palmery, M; Schiavi, S; Servadio, M; Trezza, V, 2018) |
| "We utilized a valproic acid (VPA) -induced rat model of autism to evaluate the levels of S1P and the expression of sphingosine kinase (SphK), a key enzyme for S1P production, in serum and hippocampal tissue." | 3.88 | Modulation of sphingosine 1-phosphate (S1P) attenuates spatial learning and memory impairments in the valproic acid rat model of autism. ( Cao, Y; Gao, J; Hao, Y; Sun, C; Wang, J; Wu, H; Wu, L; Xia, W; Zhang, Q, 2018) |
| "Prenatal exposure to valproic acid (VPA) induces behavioral disorders and enhancement of oxido-inflammatory stress in Autism Spectrum Disorders (ASDs)." | 3.88 | Hesperetin and it nanocrystals ameliorate social behavior deficits and oxido-inflammatory stress in rat model of autism. ( Hajizadeh Moghaddam, A; Khalaj, R; Zare, M, 2018) |
| "Considering the potential role of lymphocytes in the pathophysiology of autism spectrum disorder (ASD), we aimed to evaluate possible alterations of T cell pools in the lymphoid organs of an animal model of autism induced by valproic acid (VPA)." | 3.88 | Reduced CD4 T Lymphocytes in Lymph Nodes of the Mouse Model of Autism Induced by Valproic Acid. ( Bambini-Junior, V; Baronio, D; Bauer-Negrini, G; Castro, K; Della-Flora Nunes, G; Gottfried, C; Mendes-da-Cruz, DA; Riesgo, R; Savino, W, 2018) |
| ") on sociability, social novelty, anxiety, and aggressive/repetitive behavior in male Tuck-Ordinary (TO) mice with ASD-like behaviors induced by prenatal exposure to valproic acid (VPA, 500 mg/kg, i." | 3.88 | The histamine H3R antagonist DL77 attenuates autistic behaviors in a prenatal valproic acid-induced mouse model of autism. ( Al-Houqani, M; Azimullah, S; Eissa, N; Jalal, FY; Jayaprakash, P; Kieć-Kononowicz, K; Ojha, SK; Sadek, B; Łażewska, D, 2018) |
| "We have investigated the species richness and microbial composition in a valproic acid (VPA)-induced rat model autism." | 3.88 | The valproic acid rat model of autism presents with gut bacterial dysbiosis similar to that in human autism. ( Horton-Sparks, K; Hull, V; Li, RW; Liu, F; Martínez-Cerdeño, V, 2018) |
| " We analyzed three major types of neuroglia, astrocytes, oligodendrocytes, and microglia in the brains of an animal model of autism spectrum disorder, in which rats were exposed prenatally to antiepileptic and mood stabilizer drug valproic acid; this model being of acknowledged clinical relevance." | 3.88 | Neuroglia in the autistic brain: evidence from a preclinical model. ( Bronzuoli, MR; Facchinetti, R; Ingrassia, D; Sarvadio, M; Schiavi, S; Scuderi, C; Steardo, L; Trezza, V; Verkhratsky, A, 2018) |
| "The aim was to identify the effects of early vitamin D supplementation on autism-like behaviors (ASD) induced by valproic acid (VPA, an anti-convulsant and a mood stabilizer) in rats." | 3.85 | Behavioral improvements in a valproic acid rat model of autism following vitamin D supplementation. ( Du, L; Duan, Z; Li, F; Zhao, G, 2017) |
| "The study was performed using a rodent model of autism by exposing rat fetuses to valproic acid (VPA) on the 12." | 3.85 | Postnatal treatment using curcumin supplements to amend the damage in VPA-induced rodent models of autism. ( Al-Askar, M; Al-Ayadhi, L; Bhat, RS; El-Ansary, A; Selim, M, 2017) |
| "This 13-year-old girl with autism and intractable epilepsy experienced increased seizures; her valproic acid dose was increased and other antiepileptic drugs were administered." | 3.85 | Burst Suppression Pattern on Electroencephalogram Secondary to Valproic Acid-Induced Hyperammonemic Encephalopathy. ( Cherian, KA; Legatt, AD, 2017) |
| "N-acetylcysteine (NAC) is widely used as an antioxidant, and previous studies have suggested that it may have potential as an alternative therapeutic strategy for the treatment of patients with autism." | 3.85 | N-acetylcysteine ameliorates repetitive/stereotypic behavior due to its antioxidant properties without activation of the canonical Wnt pathway in a valproic acid-induced rat model of autism. ( Cui, W; Wen, X; Zhai, Q; Zhang, T; Zhang, Y, 2017) |
| "Recent studies have reported that oxytocin ameliorates behavioral abnormalities in both animal models and individuals with autism spectrum disorders (ASD)." | 3.85 | Oxytocin attenuates deficits in social interaction but not recognition memory in a prenatal valproic acid-induced mouse model of autism. ( Ago, Y; Hara, Y; Hasebe, S; Hashimoto, H; Higuchi, M; Matsuda, T; Nakazawa, T; Takuma, K, 2017) |
| " A 16-year-old young-boy, diagnosed with autism, developed diabetes mellitus type 1 whilst he was on treatment with olanzapine (started 4 months before), clomipramine, valproic acid and lithium." | 3.85 | Second-generation antipsychotic and diabetes mellitus in children and adolescents. ( Nurchi, AM; Pinna, AP; Podda, F; Ripoli, C; Tronci, MG; Zanni, R, 2017) |
| "The present study was undertaken to elucidate the effect of alpha-linolenic acid (ALA, 18:3, ω-3) and gamma-linolenic acid (GLA, 18:3, ω-6) on experimental autism features induced by early prenatal exposure to valproic acid (VPA) in albino wistar pups." | 3.85 | Comparative efficacy of alpha-linolenic acid and gamma-linolenic acid to attenuate valproic acid-induced autism-like features. ( Ansari, MN; Devi, U; Gautam, S; Kaithwas, G; Prakash, A; Rawat, JK; Roy, S; Saeedan, AS; Saraf, SA; Singh, M; Tiwari, V; Yadav, RK; Yadav, S, 2017) |
| "We isolated deep layer prefrontal circuits in brain slices then used single-photon GCaMP imaging to record activity from many (50 to 100) neurons simultaneously to study patterns of spontaneous activity generated by these circuits under normal conditions and in two etiologically distinct models of autism: mice exposed to valproic acid in utero and Fmr1 knockout mice." | 3.83 | Putative Microcircuit-Level Substrates for Attention Are Disrupted in Mouse Models of Autism. ( Horn, ME; Luongo, FJ; Sohal, VS, 2016) |
| "Prenatal exposure to valproic acid (VPA) in rat offspring is capable of inducing experimental autism with neurobehavioral aberrations." | 3.83 | Neuroprotective effects of docosahexaenoic acid on hippocampal cell death and learning and memory impairments in a valproic acid-induced rat autism model. ( Cao, Y; Gao, J; Liang, S; Sun, H; Wang, H; Wang, X; Wang, Y; Wu, L; Yang, F; Zhang, F, 2016) |
| "Rodents exposed prenatally to valproic acid (VPA) show autism-related behavioral abnormalities." | 3.83 | Improvement by methylphenidate and atomoxetine of social interaction deficits and recognition memory impairment in a mouse model of valproic acid-induced autism. ( Ago, Y; Hara, Y; Hasebe, S; Hashimoto, H; Katashiba, K; Matsuda, T; Onaka, Y; Takano, E; Takuma, K; Taruta, A, 2016) |
| "Exposure to valproic acid (VPA) during pregnancy has been linked with increased incidence of autism, and has repeatedly been demonstrated as a useful autism mouse model." | 3.83 | Early Behavioral Abnormalities and Perinatal Alterations of PTEN/AKT Pathway in Valproic Acid Autism Model Mice. ( Ahn, S; Kim, HS; Lee, K; Mahmood, U; Yang, EJ, 2016) |
| "Autism is a neurodevelopmental disorder, and embryonic exposure to valproic acid (VPA) in rodents is the most frequently studied environmentally triggered autism models." | 3.83 | Validation of reference genes for quantitative real-time PCR in valproic acid rat models of autism. ( Ren, J; Tian, Y; Wang, P; Wei, Z; Zhang, J; Zhang, X; Zhou, J, 2016) |
| " We differentiated and treated human SK-N-SH neuroblastoma cells with a mixture (fluoxetine, carbamazepine and venlafaxine) and valproate (used as a positive control to induce autism-associated profiles), followed by transcriptome analysis with RNA-Seq approach." | 3.83 | Psychoactive pharmaceuticals at environmental concentrations induce in vitro gene expression associated with neurological disorders. ( Kaushik, G; Thomas, MA; Xia, Y; Yang, L, 2016) |
| "Stiripentol is an antiepileptic drug (AED) approved by the European Medicines Agency for the treatment of Dravet Syndrome (DS) as adjunct treatment with valproate and clobazam." | 3.81 | Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy. ( Specchio, N; Trivisano, M; Vigevano, F, 2015) |
| "Components of the mTOR pathway were assayed by Western blotting in postmortem fusiform gyrus samples from 11 subjects with idiopathic autism and 13 controls and in valproic acid versus saline-exposed rat neocortex." | 3.81 | Decreased mTOR signaling pathway in human idiopathic autism and in rats exposed to valproic acid. ( Ahn, Y; Fahnestock, M; Michalski, B; Nicolini, C; Rho, JM, 2015) |
| "To investigate whether the decreased level of serum polyunsaturated fatty acids (PUFAs) in patients with autism is associated with the expression of related liver metabolic enzymes, we selected rats that were exposed to valproic acid (VPA) on embryonic day 12." | 3.81 | Study of the serum levels of polyunsaturated fatty acids and the expression of related liver metabolic enzymes in a rat valproate-induced autism model. ( Cao, Y; Gao, J; Hao, Y; Li, X; Liang, S; Sun, C; Wang, X; Wu, L; Xia, W; Zhao, G, 2015) |
| "Valproic acid (VPA) mouse model of autism spectrum disorder (ASD) has been characterized mostly by impaired ultrasonic vocalization, poor sociability and increased repetitive self-grooming behavior." | 3.81 | Characterization of in utero valproic acid mouse model of autism by local field potential in the hippocampus and the olfactory bulb. ( Bumrungsri, S; Chatpun, S; Cheaha, D; Kumarnsit, E, 2015) |
| "Human fetal exposure to valproic acid (VPA), a widely-used anti-epileptic and mood-stabilizing drug, leads to an increased incidence of behavioral and intellectual impairments including autism; VPA administration to pregnant rats and mice at gestational days 12." | 3.80 | Increased BDNF expression in fetal brain in the valproic acid model of autism. ( Almeida, LE; Krueger, BK; Roby, CD, 2014) |
| "We report that the oxytocin-mediated neuroprotective γ-aminobutyric acid (GABA) excitatory-inhibitory shift during delivery is abolished in the valproate and fragile X rodent models of autism." | 3.80 | Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring. ( Ben-Ari, Y; Brouchoud, C; Burnashev, N; Chazal, G; Eftekhari, S; Ferrari, DC; Khalilov, I; Lemonnier, E; Lozovaya, N; Nardou, R; Shahrokhi, A; Tsintsadze, T; Tsintsadze, V; Tyzio, R, 2014) |
| "Post natal exposure to VPA (valproic acid) in mice induces behavioral deficits, abnormal sensitivity to sensory stimuli and self-injurious behavior, observed in autism." | 3.80 | Ameliorating effect of piperine on behavioral abnormalities and oxidative markers in sodium valproate induced autism in BALB/C mice. ( Kameshwari, JS; Pragnya, B; Veeresh, B, 2014) |
| "We recently showed that prenatal exposure to valproic acid (VPA) in mice causes autism-like behavioral abnormalities, including social interaction deficits, anxiety-like behavior and spatial learning disability, in male offspring." | 3.80 | Chronic treatment with valproic acid or sodium butyrate attenuates novel object recognition deficits and hippocampal dendritic spine loss in a mouse model of autism. ( Ago, Y; Hara, Y; Hashimoto, H; Hayata-Takano, A; Kataoka, S; Kawanai, T; Maeda, Y; Matsuda, T; Takano, E; Takuma, K; Watanabe, R, 2014) |
| "Autism spectrum disorders (ASD) involve a complex interplay of both genetic and environmental risk factors, such as prenatal exposure to valproic acid (VPA)." | 3.80 | Resveratrol prevents social deficits in animal model of autism induced by valproic acid. ( Bambini-Junior, V; Della Flora Nunes, G; Fontes-Dutra, M; Gottfried, C; Michels, M; Mueller de Melo, G; Nogueira Freire, V; Riesgo, R; Zanatta, G, 2014) |
| "The aim of this work is to evaluate the impact of butyl paraben (BP) in brain of the pups developed for mothers administered BP from early pregnancy till weaning and its effect on studying the behavior, brain neurotransmitters and brain derived neurotrophic factor BDNF via comparing the results with valproic acid (VA) autistic-rat model preparing by a single oral injection dose of VA (800 mg/kg b." | 3.79 | Combined prenatal and postnatal butyl paraben exposure produces autism-like symptoms in offspring: comparison with valproic acid autistic model. ( Ali, EH; Elgoly, AH, 2013) |
| "Maternal use of valproic acid (VPA) during pregnancy has been implicated in the aetiology of autism spectrum disorders in children, and rodents prenatally exposed to VPA showed behavioural alterations similar to those observed in humans with autism." | 3.79 | Autism-like behaviours with transient histone hyperacetylation in mice treated prenatally with valproic acid. ( Ago, Y; Hara, Y; Kataoka, S; Maeda, Y; Matsuda, T; Takuma, K, 2013) |
| "Prenatal exposure to valproic acid (VPA) induces neural tube defects and impairment in social behaviors related to autistic spectrum disorder in newborns, which make it a useful animal model of autism." | 3.77 | The critical period of valproate exposure to induce autistic symptoms in Sprague-Dawley rats. ( Cheong, JH; Choi, CS; Go, HS; Kim, KC; Kim, P; Ko, KH; Shin, CY; Yang, SI, 2011) |
| "Rats exposed to valproic acid (VPA) on gestational day 12 (GD12) have been advanced as a rodent model of autism [Arndt TL, Stodgell, Rodier PM." | 3.75 | Interstimulus interval (ISI) discrimination of the conditioned eyeblink response in a rodent model of autism. ( Brown, KL; Murawski, NJ; Stanton, ME, 2009) |
| "Offspring of rats exposed to valproic acid (VPA) on gestational day (GD) 12 have been advocated as a rodent model of autism because they show neuron loss in brainstem nuclei and the cerebellum resembling that seen in human autistic cases ." | 3.74 | Discrimination learning and reversal of the conditioned eyeblink reflex in a rodent model of autism. ( Brown, KL; Peloso, E; Rodier, P; Stanton, ME, 2007) |
| " Using rats exposed prenatally to valproic acid (VPA) as an animal model of autism, we examined locomotor activity and feeding under a reversed 12-h light/dark cycle, and found disturbance of the circadian rhythm characterized by frequent arousal during the light/sleep phase." | 3.74 | Abnormality of circadian rhythm accompanied by an increase in frontal cortex serotonin in animal model of autism. ( Arita, H; Nakamura, M; Nakasato, A; Nakatani, Y; Seki, Y; Sugawara, M; Tsujino, N, 2007) |
| "Exposure to valproic acid (VPA) during embryogenesis can cause several teratogenic effects, including developmental delays and in particular autism in humans if exposure occurs during the third week of gestation." | 3.74 | Hyperconnectivity of local neocortical microcircuitry induced by prenatal exposure to valproic acid. ( Markram, H; Rinaldi, T; Silberberg, G, 2008) |
| "Autism is a neurodevelopmental disorder characterized by impairment in three core symptom domains: socialization, communication, and repetitive/stereotyped behaviours." | 2.72 | Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. ( Anagnostou, E; Chaplin, W; Esposito, K; Hollander, E; Soorya, L; Wasserman, S, 2006) |
| "The term of autism spectrum disorders (ASD) is used to account for the diversity of symptoms that characterize this pathology." | 2.61 | [The valproate model of autism]. ( Bossu, JL; Roux, S, 2019) |
| "Valproic acid (VPA) is an anticonvulsant and mood stabilizer that, when used during the gestational period, increases the risk of ASD in the offspring." | 2.58 | Neuroimmune Alterations in Autism: A Translational Analysis Focusing on the Animal Model of Autism Induced by Prenatal Exposure to Valproic Acid. ( Bambini-Junior, V; Deckmann, I; Fontes-Dutra, M; Gottfried, C; Schwingel, GB, 2018) |
| "Valproic acid (VPA) is a known human teratogen." | 2.45 | Valproic acid in pregnancy: how much are we endangering the embryo and fetus? ( Ornoy, A, 2009) |
| "Valproic acid (VPA) is an effective drug, which is preferred for the treatments of epilepsy and various kinds of seizures." | 2.44 | The effects of valproic acid neurotoxicity on aggressive behavior in zebrafish autism model. ( Feng, T; Li, X; Lu, W, 2024) |
| "When treatment with valproic acid is the most appropriate treatment to achieve optimal seizure control, a number of measures can be implemented to minimise risk to the fetus." | 2.43 | Valproic acid in epilepsy : pregnancy-related issues. ( Genton, P; Semah, F; Trinka, E, 2006) |
| "Thymol is a bioactive monoterpene isolated from Thymus vulgaris that has anti-inflammatory properties and is helpful in neurodevelopmental disorders." | 1.91 | Thymol improves autism-like behaviour in VPA-induced ASD rats through the Pin1/p38 MAPK pathway. ( Chen, J; Li, Y; Lv, M; Tang, B; Wang, F; Xiong, Y; Zhang, H, 2023) |
| " The repetitive behaviors were ameliorated relatively in VPA groups with NEPO2000 treatment, and astrogliosis was reduced even when VPA rats were treated with a lower dosage of NEPO." | 1.91 | Astrocyte responses to postnatal erythropoietin and nano-erythropoietin treatments in a valproic acid-induced animal model of autism. ( Basiri, M; Haratizadeh, S; Nozari, M; Ranjbar, M, 2023) |
| "Autism spectrum disorder is characterized by a variety of cellular and molecular abnormalities which leads to autism-associated behaviors." | 1.91 | Chronic acetyl-L-carnitine treatment alleviates behavioral deficits and neuroinflammation through enhancing microbiota derived-SCFA in valproate model of autism. ( Roghani, M; Sadr, SS; Sanaeierad, A; Zahedi, E, 2023) |
| "Many studies show that the number of cognitive impairmentscan be reduced by antagonists of the histamine H3 receptor (H3R)." | 1.91 | Amelioration of cognition impairments in the valproic acid-induced animal model of autism by ciproxifan, a histamine H3-receptor antagonist. ( Esmaeilpour, K; Sepehri, G; Sheibani, V; Shekari, MA; Taheri, F, 2023) |
| "Autism is a neurodevelopmental condition, and it's associated pathophysiology, viz." | 1.91 | Neuroprotective Efficacy of Fisetin Against VPA-Induced Autistic Neurobehavioral Alterations by Targeting Dysregulated Redox Homeostasis. ( Ahsan, AU; Budhwar, M; Chopra, M; Mehra, S; Sharma, M, 2023) |
| "Autism has a strong genetic and heritable component; however, environmental factors including toxins, pesticides, infection and in utero exposure to drugs such as VPA have also been implicated in ASD." | 1.91 | Striatal synaptic changes and behavior in adult mouse upon prenatal exposure to valproic acid. ( Delgado-González, E; Durairaj, RV; Espinosa, F; Hernandez, A; Martínez-Torres, A; Reyes-Haro, D, 2023) |
| "Valproic acid (VPA) is a well-known anti-epileptic drug, but its prenatal exposure to animals causes social impairment, neurotransmitters imbalance, and neuroinflammation with ASD-like phenotypes." | 1.91 | Syringic acid alleviates valproic acid induced autism via activation of p38 mitogen-activated protein kinase: Possible molecular approach. ( Mallan, S; Singh, S, 2023) |
| "Valproic acid (VPA) was administrated once on gestational day 12." | 1.91 | Sex-related beneficial effects of exercise on cardiac function and rhythm in autistic rats. ( Bashiri, H; Jafari, E; Moslemizadeh, A; Rajizadeh, MA; Rostamzadeh, F; Sabet, N, 2023) |
| "Autism is a neurobehavioral disease that induces cognitive and behavioral alterations, usually accompanied by oxidative stress in the brain." | 1.91 | Saffron and crocin ameliorate prenatal valproic acid-induced autistic-like behaviors and brain oxidative stress in the male offspring rats. ( Abbarin, D; Raise-Abdullahi, P; Rashidy-Pour, A; Sedaghat, K; Seyedinia, SA; Tarahomi, P; Vafaei, AA; Yaribeygi, H, 2023) |
| "Investigations into the etiology of autism spectrum disorders have been largely confined to two realms: variations in DNA sequence and somatic developmental exposures." | 1.72 | Beyond Genes: Germline Disruption in the Etiology of Autism Spectrum Disorders. ( Corces, VG; Escher, J; Hernandez, A; Rissman, EF; Wang, HV; Yan, W, 2022) |
| "Autism is a neurobiological developmental disorder characterized by poor social interaction and communication, narrow interests, and stereotyped behaviors." | 1.72 | [Epigenetic mechanisms involved in the genesis of autism]. ( Arberas, C; Ruggieri, V, 2022) |
| "A core yet understudied symptom of autism is aberrant eating behaviour, including extremely narrow food preferences." | 1.72 | Mild Hypophagia and Associated Changes in Feeding-Related Gene Expression and c-Fos Immunoreactivity in Adult Male Rats with Sodium Valproate-Induced Autism. ( Klockars, A; Laloli, KJ; Moscrip, CA; Olszewski, PK; Pal, T, 2022) |
| "The mouse model of autism induced by prenatal exposure to valproic acid (VPA) was used to assess the therapeutic potential of STX209 on autism‑like behaviour in the present study." | 1.72 | The GABAB receptor agonist STX209 reverses the autism‑like behaviour in an animal model of autism induced by prenatal exposure to valproic acid. ( Chang, H; Ding, J; Gao, C; He, M; Jiang, S; Li, W; Sun, T; Sun, Y; Wang, F; Wang, Y; Xiao, L; Zhu, C, 2022) |
| "Valproic acid (VPA) was administered intraperitoneally at doses of 500 mg/kg to female rats during gestational 12." | 1.72 | Sumac and gallic acid-loaded nanophytosomes ameliorate hippocampal oxidative stress via regulation of Nrf2/Keap1 pathway in autistic rats. ( Abbasalipour, H; Hajizadeh Moghaddam, A; Ranjbar, M, 2022) |
| " Pregnant C57BL/6 J mice were intraperitoneally injected with a dosage of 500 mg/kg valproic acid (VPA) on embryonic day 10." | 1.72 | Size anomaly and alteration of GABAergic enzymes expressions in cerebellum of a valproic acid mouse model of autism. ( Kwan, KM; Ma, SY, 2022) |
| "However, the development of the autism-related gut microbiota and its relationship with intestinal dysfunction in ASD remain unclear." | 1.72 | Congenitally underdeveloped intestine drives autism-related gut microbiota and behavior. ( Chen, M; Cheng, M; Gao, X; He, Y; Li, H; Li, J; Li, Z; Liu, F; Meng, F; Qing, W; Shen, W; Shi, Y; Wang, H; Wang, Q; Wu, F; Zeng, N; Zhou, H, 2022) |
| "Autism spectrum disorder is a neurodevelopmental disorder characterized by sensory abnormalities, social skills impairment and cognitive deficits." | 1.72 | Alterations in the intrinsic discharge activity of CA1 pyramidal neurons associated with possible changes in the NADPH diaphorase activity in a rat model of autism induced by prenatal exposure to valproic acid. ( Behzadi, G; Borjkhani, M; Davoudi, S; Hajisoltani, R; Hosseinmardi, N; Janahmadi, M; Karimi, SA; Khatibi, VA; Rahdar, M, 2022) |
| "Previous studies have indicated that autism-like behavioral phenotypes detected in F1 VPA mice transgenetically appear in F2 and F3 generations." | 1.72 | Early-onset of social communication and locomotion activity in F2 pups of a valproic acid-induced mouse model of autism. ( Fu, P; Furuhara, K; Higashida, H; Minami, K; Mizutani, R; Tsuji, C; Tsuji, T; Yokoyama, S; Zhong, J, 2022) |
| "Melatonin is an endogenous hormone and can restore gut microbial dysbiosis under various disease conditions." | 1.72 | Rescue of social deficits by early-life melatonin supplementation through modulation of gut microbiota in a murine model of autism. ( Cui, Y; Li, XG; Liu, W; Liu, X; Qiu, B; Wang, X; Xiang, G; Yu, M; Zhang, D; Zhang, Y, 2022) |
| "Autism is characterized by two key diagnostic criteria including social deficits and repetitive behaviors." | 1.72 | Differential Alterations in Striatal Direct and Indirect Pathways Mediate Two Autism-like Behaviors in Valproate-Exposed Mice. ( Cheng, Q; Di, Y; Diao, Z; Fan, J; Fang, S; Han, J; Li, J; Li, Z; Liu, Y; Liu, Z; Ren, W; Tian, Y; Wang, H; Wei, C; Zheng, Q, 2022) |
| "Valproic acid (VPA) is an antiepileptic drug with a pronounced teratogenic effect associated with a high risk of ASD, and its administration to rats during the gestation is used for autism modeling." | 1.62 | Assessment of behavioral, morphological and electrophysiological changes in prenatal and postnatal valproate induced rat models of autism spectrum disorder. ( Chavushyan, V; Danielyan, M; Fereshetyan, K; Yenkoyan, K, 2021) |
| "Despite the increasing prevalence of autism spectrum disorder (ASD), there is still a deficiency in understanding its exact pathophysiology and treatment, therefore validation of translational ASD animal model is warranted." | 1.62 | Validation of prenatal versus postnatal valproic acid rat models of autism: A behavioral and neurobiological study. ( Abdelraouf, SM; Aboul-Fotouh, S; Abuelezz, SA; Ahmed, AI; Bahaa, N; Elnahas, EM; Hassan, GA; Ibrahim, EA; Mohamad, MI; Nabil, MM, 2021) |
| "These results showed that VAD in autism might result in cerebellar impairments and be a factor aggravating a subtype of ASD with motor comorbidities." | 1.62 | Vitamin A supplementation ameliorates motor incoordination via modulating RORα in the cerebellum in a valproic acid-treated rat autism model with vitamin A deficiency. ( Cheng, B; Hou, N; Li, L; Li, T; Liu, H; Wang, S; Wu, Q; Yang, T, 2021) |
| "Suramin treatment did not affect VPA-induced upregulation of P2X4 and P2Y2 receptor expression in the hippocampus, and P2X4 receptor expression in the medial prefrontal cortex, but normalized an increased level of interleukin 6 (IL-6)." | 1.56 | Effects of single-dose antipurinergic therapy on behavioral and molecular alterations in the valproic acid-induced animal model of autism. ( Bambini-Junior, V; Bauer-Negrini, G; Brum Schwingel, G; Carello-Collar, G; Castillo, ARG; Corrêa-Velloso, J; Deckmann, I; Fontes-Dutra, M; Gonçalves, MCB; Gottfried, C; Hirsch, MM; Körbes-Rockenbach, M; Naaldijk, Y; Rabelo, B; Santos-Terra, J; Schneider, T; Staevie, GZ; Ulrich, H, 2020) |
| "Quercetin (50 mg/kg) was administered orally to the animals from gestational days 6." | 1.56 | Quercetin prevents alterations of behavioral parameters, delta-aminolevulinic dehydratase activity, and oxidative damage in brain of rats in a prenatal model of autism. ( Baldissarelli, J; de Mattos, BDS; de Souza, AA; Gamaro, GD; Pedra, NS; Soares, MSP; Spanevello, RM; Spohr, L; Stefanello, FM; Teixeira, FC, 2020) |
| "The manifestations of autism spectrum disorder (ASD) are highly heterogeneous." | 1.56 | Vitamin A deficiency exacerbates autism-like behaviors and abnormalities of the enteric nervous system in a valproic acid-induced rat model of autism. ( Chen, J; Cheng, B; Li, T; Liu, H; Wang, S; Wu, Q; Yang, T; Zhang, X; Zhu, J, 2020) |
| "The social motivational theory of autism spectrum disorder (ASD) focuses on social anhedonia as key causal feature of the impaired peer relationships that characterize ASD patients." | 1.56 | Targeting PPARα in the rat valproic acid model of autism: focus on social motivational impairment and sex-related differences. ( Braccagni, G; De Montis, MG; Gambarana, C; Guzzi, F; Parenti, M; Scheggi, S, 2020) |
| "Autism is far more prevalent in males than females, and sex-specific properties of PCs have been reported recently." | 1.51 | Regional and sex-dependent alterations in Purkinje cell density in the valproate mouse model of autism. ( Bailly, Y; Bossu, JL; Roux, S, 2019) |
| "Autism is characterized by numerous behavioral impairments, such as in communication, socialization and cognition." | 1.48 | Zinc as a therapy in a rat model of autism prenatally induced by valproic acid. ( Bernardi, MM; Cezar, LC; da Fonseca, CCN; de Lima, APN; Felicio, LF; Kirsten, TB, 2018) |
| "Rats of the VPA model of autism showed reduced total reciprocal social interaction, prevented by prenatal treatment with resveratrol (RSV)." | 1.48 | Behavioral alterations in autism model induced by valproic acid and translational analysis of circulating microRNA. ( Bambini-Junior, V; Bauer-Negrini, G; Deckmann, I; Della-Flora Nunes, G; Fontes-Dutra, M; Gottfried, C; Hirsch, MM; Margis, R; Nunes, W; Rabelo, B; Riesgo, R, 2018) |
| "The etiology of autism remains unknown and its molecular basis is not yet well understood." | 1.48 | Social behavior, neuroimmune markers and glutamic acid decarboxylase levels in a rat model of valproic acid-induced autism. ( Imai, M; Lwin, TT; Mar, O; Nway, NC; Watanabe, H; Win-Shwe, TT, 2018) |
| "The novel therapeutic strategy against autism is essential due to the limited therapeutic efficacy." | 1.46 | Laser Acupuncture at HT7 Improves the Cerebellar Disorders in Valproic Acid-Rat Model of Autism. ( Khongrum, J; Wattanathorn, J, 2017) |
| "Males are predominantly affected by autism spectrum disorders (ASD) with a prevalence ratio of 5:1." | 1.43 | MeCP2 Modulates Sex Differences in the Postsynaptic Development of the Valproate Animal Model of Autism. ( Cheong, JH; Choi, CS; Han, SH; Kim, JW; Kim, KC; Ryu, JH; Shin, CY, 2016) |
| "Autism is a neurodevelopment disorder." | 1.43 | Minocycline ameliorates prenatal valproic acid induced autistic behaviour, biochemistry and blood brain barrier impairments in rats. ( Kumar, H; Sharma, B, 2016) |
| "Treatment with memantine has significantly attenuated prenatal valproic acid-induced reduction in social interaction, spontaneous alteration, exploratory activity intestinal motility, serotonin levels and prefrontal cortex mitochondrial complex activity." | 1.43 | Memantine ameliorates autistic behavior, biochemistry & blood brain barrier impairments in rats. ( Kumar, H; Sharma, B, 2016) |
| "Valproic acid (VPA) is a multi-target drug and an inhibitor of histone deacetylase (HDAC)." | 1.43 | Prenatal Exposure to Histone Deacetylase Inhibitors Affects Gene Expression of Autism-Related Molecules and Delays Neuronal Maturation. ( Ago, Y; Hasebe, S; Hashimoto, H; Inoue, A; Kawanai, T; Matsuda, T; Onaka, Y; Takuma, K; Taruta, A; Watanabe, R, 2016) |
| "Autism is a severe neurodevelopmental disorder with a population prevalence of 1 in 68, and dramatically increasing." | 1.42 | Tactile stimulation improves neuroanatomical pathology but not behavior in rats prenatally exposed to valproic acid. ( Gibb, R; Harker, A; Kolb, B; Raza, S; Richards, S, 2015) |
| " The treatment was started on the 5th day after STZ injection with the same dose as in group II and it was considered as 1st day of treatment with gold nanoparticles for 7 days to each rat of (group IV) treated autistic diabetic group(TAD) at a dosage of 2." | 1.42 | Pancreatic response to gold nanoparticles includes decrease of oxidative stress and inflammation in autistic diabetic model. ( Abd-Elhakim, YM; Al-Ayadhi, LY; Selim, ME, 2015) |
| "Valproic acid (600 mg/kg) was administered intraperitoneally to the pregnant mice on gestational day 12." | 1.42 | Astaxanthin improves behavioral disorder and oxidative stress in prenatal valproic acid-induced mice model of autism. ( Al-Amin, MM; Khan, FR; Mahmud Reza, H; Rahman, MM; Zaman, F, 2015) |
| "Most cases of idiopathic autism spectrum disorder (ASD) likely result from unknown environmental triggers in genetically susceptible individuals." | 1.42 | Psychoactive pharmaceuticals as environmental contaminants may disrupt highly inter-connected nodes in an Autism-associated protein-protein interaction network. ( Aho, KA; Kaushik, G; Thomas, MA, 2015) |
| "Although animal models of autism have demonstrated that model animals engage less in social interaction or attend less to conspecifics than control animals, no animal model has yet replicated the deficit in recognition of complex social interaction as is seen in humans with autism." | 1.42 | Indifference of marmosets with prenatal valproate exposure to third-party non-reciprocal interactions with otherwise avoided non-reciprocal individuals. ( Banno, T; Ichinohe, N; Kawai, N; Nakagaki, K; Nakagami, A; Yasue, M, 2015) |
| "A major focus of animal models of autism has been to mimic the social deficits of the disorder." | 1.42 | Effects of prenatal exposure to valproic acid on the development of juvenile-typical social play in rats. ( Gibb, R; Harker, A; Himmler, BT; Himmler, SM; Kolb, B; Pellis, SM; Raza, S, 2015) |
| "The therapeutic strategy against autism, a severe neurological development disorder, is one of the challenges of this decade." | 1.42 | Laser Acupuncture Improves Behavioral Disorders and Brain Oxidative Stress Status in the Valproic Acid Rat Model of Autism. ( Khongrum, J; Wattanathorn, J, 2015) |
| "Previously, autism spectrum disorder (ASD) has been identified mainly by social communication deficits and behavioral symptoms." | 1.42 | Alteration of spontaneous spectral powers and coherences of local field potential in prenatal valproic acid mouse model of autism. ( Cheaha, D; Kumarnsit, E, 2015) |
| "It is further posited that, in autism, the drugs act as "triggers" that disturb the pro-proliferative fetal milieu using the same, mainly epigenetic, mechanisms that they demonstrate in rapidly proliferating cancer cells." | 1.40 | Autism's cancer connection: the anti-proliferation hypothesis and why it may matter. ( Ward, CS, 2014) |
| "Valproic acid (VPA) is an anticonvulsant that is a known risk factor for autism in prenatally exposed children." | 1.40 | Degraded auditory processing in a rat model of autism limits the speech representation in non-primary auditory cortex. ( Borland, MS; Carraway, RS; Centanni, TM; Engineer, CT; Im, KW; Kilgard, MP; Moreno, NA; Wilson, LG, 2014) |
| "Valproate is used for the treatment of epilepsy and other neuropsychological disorders and may be the only treatment option for women of childbearing potential." | 1.39 | Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. ( Christensen, J; Grønborg, TK; Parner, ET; Pedersen, LH; Schendel, D; Sørensen, MJ; Vestergaard, M, 2013) |
| "Abnormalities of the cerebellum in autism include Purkinje cell loss and motor disturbance." | 1.39 | Treadmill exercise ameliorates motor disturbance through inhibition of apoptosis in the cerebellum of valproic acid-induced autistic rat pups. ( Baek, SS; Ji, ES; Kim, CJ; Kim, JE; Lee, SJ; Park, JK; Seo, TB; Shin, MS, 2013) |
| "Autism is characterized by behavioral impairments in three main domains: social interaction; language, communication and imaginative play; and the range of interests and activities." | 1.39 | Increased hippocampal cell density and enhanced spatial memory in the valproic acid rat model of autism. ( Edalatmanesh, MA; Moghadas, M; Nikfarjam, H; Vafaee, F, 2013) |
| "The biological mechanisms of autism spectrum disorders (ASDs) are largely unknown in spite of extensive research." | 1.39 | Impairment of cortical GABAergic synaptic transmission in an environmental rat model of autism. ( Atzori, M; Banerjee, A; Galindo, LC; García-Oscos, F; Hall, S; Kilgard, MP; Roychowdhury, S, 2013) |
| "However, the role of the amygdala in autism remains inconclusive." | 1.39 | The amygdala excitatory/inhibitory balance in a valproate-induced rat autism model. ( Chan, YH; Chen, PS; Gean, PW; Lin, HC; Wang, CC, 2013) |
| "monniera on VPA induced autism." | 1.38 | Bacopa monniera (L.) Wettst ameliorates behavioral alterations and oxidative markers in sodium valproate induced autism in rats. ( Sandhya, T; Sowjanya, J; Veeresh, B, 2012) |
| "Although autism is diagnosed according to three core features of social deficits, communication impairments, and repetitive or stereotyped behaviors, other behavioral features such as sensory and motor impairments are present in more than 70% of individuals with autism spectrum disorders (ASD)." | 1.38 | Sensory and motor characterization in the postnatal valproate rat model of autism. ( Devine, DP; Millette, A; Reynolds, S, 2012) |
| "In order to establish the etiology of autism with facial palsy, research into developmental abnormalities of the peripheral facial nerves is necessary." | 1.37 | Morphological abnormalities of embryonic cranial nerves after in utero exposure to valproic acid: implications for the pathogenesis of autism with multiple developmental anomalies. ( Imura, Y; Narita, M; Narita, N; Oyabu, A; Tashiro, Y; Uchida, A, 2011) |
| "Despite the prevalence of autism, the neurobiology of this disorder is poorly understood." | 1.37 | Malformation of the superior olivary complex in an animal model of autism. ( Kulesza, RJ; Lukose, R; Murawski, NJ; Schmidt, E; Wolski, TP, 2011) |
| "Autism is characterized by behavioral impairments in three main domains: social interaction; language, communication and imaginative play; and range of interests and activities." | 1.37 | Animal model of autism induced by prenatal exposure to valproate: behavioral changes and liver parameters. ( Bambini-Junior, V; Behr, GA; Gottfried, C; Moreira, JC; Riesgo, R; Rodrigues, L, 2011) |
| "Autism is a behaviorally characterized disorder with impairments in social interactions, as well as stereotyped, repetitive patterns of behaviors and interests." | 1.36 | Nonexploratory movement and behavioral alterations in a thalidomide or valproic acid-induced autism model rat. ( Imura, Y; Kamada, N; Narita, M; Narita, N; Oyabu, A; Tano, K; Uchida, A; Yokoyama, T, 2010) |
| "Approximately 30% of individuals with autism have normal development up to the age of about 30 months after which they experience behavioral regression and lose previously acquired motor, cognitive and social skills." | 1.36 | Animal model of autism using GSTM1 knockout mice and early post-natal sodium valproate treatment. ( Bhattacharya, P; Mirochnitchenko, O; Patti, L; Wagner, GC; Yochum, CL, 2010) |
| "Autism is a behaviourally defined neurodevelopmental disorder with unknown etiology." | 1.36 | Altering the trajectory of early postnatal cortical development can lead to structural and behavioural features of autism. ( Block, E; Chomiak, T; Hu, B; Karnik, V, 2010) |
| "Epilepsy was diagnosed in 37% (375/1014) of the study participants." | 1.36 | Correlation between EEG abnormalities and symptoms of autism spectrum disorder (ASD). ( Yasuhara, A, 2010) |
| "A core feature of autism spectrum disorders is the impairment in social interactions." | 1.35 | Abnormal fear conditioning and amygdala processing in an animal model of autism. ( La Mendola, D; Markram, H; Markram, K; Rinaldi, T; Sandi, C, 2008) |
| "Autism is a severe behavioral disorder characterized by pervasive impairments in social interactions, deficits in verbal and non-verbal communication, and stereotyped behaviors, with a four times higher incidence in boys than in girls." | 1.35 | Gender-specific behavioral and immunological alterations in an animal model of autism induced by prenatal exposure to valproic acid. ( Basta-Kaim, A; Budziszewska, B; Kubera, M; Przewłocki, R; Roman, A; Schneider, K; Schneider, T, 2008) |
| "Recently, a new rodent model of autism was created by exposure of rat fetuses to valproic acid (VPA) on the 12." | 1.33 | Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. ( Przewłocki, R; Schneider, T, 2005) |
| "Morphologic abnormalities found in autism (e." | 1.31 | Increased monoamine concentration in the brain and blood of fetal thalidomide- and valproic acid-exposed rat: putative animal models for autism. ( Kato, M; Miyazaki, K; Narita, M; Narita, N; Okado, N; Tazoe, M, 2002) |
| "Autism has been described in association with a variety of medical and genetic conditions." | 1.31 | Fetal valproate syndrome and autism: additional evidence of an association. ( Cunningham, M; Hersh, JH; Kerr, B; King, J; Stephan, M; Williams, G, 2001) |
| "A possible causal relationship between autism and absence seizures in these children is explored." | 1.30 | Valproic acid treatment of epilepsy in autistic twins. ( Blair, JL; Childs, JA, 1997) |
| "One also had features of infantile autism." | 1.29 | Fetal valproate syndrome: clinical and neuro-developmental features in two sibling pairs. ( Chesler, N; Christianson, AL; Kromberg, JG, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.38) | 18.7374 |
| 1990's | 7 (2.67) | 18.2507 |
| 2000's | 30 (11.45) | 29.6817 |
| 2010's | 128 (48.85) | 24.3611 |
| 2020's | 96 (36.64) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, Y | 1 |
| Han, Y | 2 |
| Ren, S | 1 |
| Zhang, B | 2 |
| Zhao, Y | 1 |
| Wang, X | 8 |
| Zhang, S | 1 |
| Qin, J | 2 |
| Escher, J | 1 |
| Yan, W | 1 |
| Rissman, EF | 1 |
| Wang, HV | 1 |
| Hernandez, A | 2 |
| Corces, VG | 1 |
| Fereshetyan, K | 1 |
| Chavushyan, V | 1 |
| Danielyan, M | 1 |
| Yenkoyan, K | 1 |
| Gu, YY | 1 |
| Liang, JJ | 1 |
| Cui, YN | 1 |
| Zhang, Y | 8 |
| Zhang, SB | 1 |
| Elnahas, EM | 3 |
| Abuelezz, SA | 2 |
| Mohamad, MI | 3 |
| Nabil, MM | 2 |
| Abdelraouf, SM | 2 |
| Bahaa, N | 2 |
| Hassan, GAM | 2 |
| Aboul-Fotouh, S | 4 |
| Vakili Shahrbabaki, SS | 1 |
| Jonaidi, H | 1 |
| Sheibani, V | 5 |
| Bashiri, H | 4 |
| Ruggieri, V | 1 |
| Arberas, C | 1 |
| Cheng, Y | 1 |
| Tang, B | 3 |
| Zhang, G | 1 |
| An, P | 1 |
| Sun, Y | 3 |
| Gao, M | 1 |
| Shan, Y | 1 |
| Zhang, J | 3 |
| Liu, Q | 1 |
| Lai, CSW | 1 |
| de Villers-Sidani, É | 1 |
| Wang, Y | 3 |
| Zhou, X | 1 |
| Bódi, V | 1 |
| Májer, T | 1 |
| Kelemen, V | 1 |
| Világi, I | 1 |
| Szűcs, A | 1 |
| Varró, P | 1 |
| Pal, T | 1 |
| Laloli, KJ | 1 |
| Moscrip, CA | 1 |
| Olszewski, PK | 1 |
| Klockars, A | 1 |
| Jiang, S | 1 |
| Xiao, L | 1 |
| He, M | 1 |
| Gao, C | 1 |
| Zhu, C | 1 |
| Chang, H | 1 |
| Ding, J | 1 |
| Li, W | 1 |
| Sun, T | 1 |
| Wang, F | 2 |
| Santrač, A | 1 |
| Bijelić, D | 1 |
| Stevanović, V | 1 |
| Banićević, M | 1 |
| Aranđelović, J | 1 |
| Batinić, B | 1 |
| Sharmin, D | 1 |
| Cook, JM | 1 |
| Savić, MM | 1 |
| Abbasalipour, H | 1 |
| Hajizadeh Moghaddam, A | 2 |
| Ranjbar, M | 3 |
| Meng, Q | 1 |
| Zhang, W | 1 |
| Jiao, C | 1 |
| Xu, S | 1 |
| Liu, C | 2 |
| Chen, C | 1 |
| Imam, B | 1 |
| Rahmatinia, M | 1 |
| Shahsavani, A | 1 |
| Khodagholi, F | 1 |
| Hopke, PK | 1 |
| Bazazzpour, S | 1 |
| Hadei, M | 1 |
| Yarahmadi, M | 1 |
| Abdollahifar, MA | 1 |
| Torkmahalleh, MA | 1 |
| Kermani, M | 1 |
| Ilkhani, S | 1 |
| MirBehbahani, SH | 1 |
| Ma, SY | 1 |
| Kwan, KM | 1 |
| Elesawy, RO | 1 |
| El-Deeb, OS | 1 |
| Eltokhy, AK | 1 |
| Arakeep, HM | 1 |
| Ali, DA | 1 |
| Elkholy, SS | 1 |
| Kabel, AM | 1 |
| Santos-Terra, J | 2 |
| Deckmann, I | 4 |
| Carello-Collar, G | 2 |
| Nunes, GD | 2 |
| Bauer-Negrini, G | 4 |
| Schwingel, GB | 2 |
| Fontes-Dutra, M | 5 |
| Riesgo, R | 7 |
| Gottfried, C | 9 |
| Seiffe, A | 1 |
| Ramírez, MF | 1 |
| Sempé, L | 1 |
| Depino, AM | 1 |
| Taheri, F | 3 |
| Esmaeilpour, K | 3 |
| Sepehri, G | 3 |
| Ur Rehman, N | 1 |
| Maneshian, M | 1 |
| Liu, Z | 4 |
| Wang, J | 5 |
| Xu, Q | 1 |
| Wu, Z | 1 |
| You, L | 1 |
| Hong, Q | 1 |
| Zhu, J | 2 |
| Chi, X | 1 |
| Mehra, S | 2 |
| Ul Ahsan, A | 1 |
| Seth, E | 1 |
| Chopra, M | 2 |
| Dufour, A | 1 |
| Dumon, C | 1 |
| Gouty-Colomer, LA | 1 |
| Eftekhari, S | 2 |
| Ferrari, DC | 2 |
| Ben-Ari, Y | 2 |
| Bjørk, MH | 1 |
| Zoega, H | 1 |
| Leinonen, MK | 1 |
| Cohen, JM | 1 |
| Dreier, JW | 1 |
| Furu, K | 1 |
| Gilhus, NE | 1 |
| Gissler, M | 1 |
| Hálfdánarson, Ó | 1 |
| Igland, J | 1 |
| Tomson, T | 1 |
| Alvestad, S | 1 |
| Christensen, J | 2 |
| Sivasangari, K | 1 |
| Rajan, KE | 1 |
| Li, J | 5 |
| Wang, H | 7 |
| Qing, W | 1 |
| Liu, F | 2 |
| Zeng, N | 1 |
| Wu, F | 1 |
| Shi, Y | 1 |
| Gao, X | 1 |
| Cheng, M | 1 |
| Li, H | 1 |
| Shen, W | 1 |
| Meng, F | 1 |
| He, Y | 1 |
| Chen, M | 1 |
| Li, Z | 5 |
| Zhou, H | 1 |
| Wang, Q | 1 |
| Jian, J | 1 |
| Li, LG | 1 |
| Zhao, PJ | 1 |
| Zheng, RJ | 1 |
| Dong, XW | 1 |
| Zhao, YH | 1 |
| Yin, BQ | 1 |
| Cheng, H | 1 |
| Li, HL | 1 |
| Li, EY | 1 |
| Avolio, E | 2 |
| Olivito, I | 2 |
| Rosina, E | 1 |
| Romano, L | 1 |
| Angelone, T | 1 |
| De Bartolo, A | 1 |
| Scimeca, M | 1 |
| Bellizzi, D | 1 |
| D'Aquila, P | 1 |
| Passarino, G | 1 |
| Alò, R | 2 |
| Facciolo, RM | 2 |
| Bagni, C | 1 |
| De Lorenzo, A | 1 |
| Canonaco, M | 2 |
| Alpay, M | 1 |
| Yucel, F | 1 |
| Rahdar, M | 2 |
| Hajisoltani, R | 1 |
| Davoudi, S | 2 |
| Karimi, SA | 1 |
| Borjkhani, M | 1 |
| Khatibi, VA | 1 |
| Hosseinmardi, N | 2 |
| Behzadi, G | 2 |
| Janahmadi, M | 2 |
| Tsuji, C | 1 |
| Furuhara, K | 1 |
| Mizutani, R | 1 |
| Minami, K | 1 |
| Fu, P | 1 |
| Zhong, J | 1 |
| Higashida, H | 1 |
| Yokoyama, S | 1 |
| Tsuji, T | 1 |
| Serra, D | 1 |
| Henriques, JF | 1 |
| Sousa, FJ | 1 |
| Laranjo, M | 1 |
| Resende, R | 1 |
| Ferreira-Marques, M | 1 |
| de Freitas, V | 1 |
| Silva, G | 1 |
| Peça, J | 1 |
| Dinis, TCP | 1 |
| Almeida, LM | 1 |
| Zhou, B | 1 |
| Yan, X | 1 |
| Yang, L | 2 |
| Zheng, X | 1 |
| Chen, Y | 1 |
| Liu, Y | 6 |
| Ren, Y | 1 |
| Peng, J | 1 |
| Huang, J | 1 |
| Tang, L | 1 |
| Wen, M | 1 |
| Liu, X | 3 |
| Cui, Y | 3 |
| Xiang, G | 3 |
| Yu, M | 3 |
| Qiu, B | 3 |
| Li, XG | 3 |
| Liu, W | 3 |
| Zhang, D | 3 |
| Di, Y | 5 |
| Diao, Z | 3 |
| Zheng, Q | 7 |
| Cheng, Q | 4 |
| Fang, S | 3 |
| Wei, C | 4 |
| Han, J | 4 |
| Fan, J | 4 |
| Ren, W | 5 |
| Tian, Y | 8 |
| Galineau, L | 3 |
| Arlicot, N | 3 |
| Dupont, AC | 3 |
| Briend, F | 3 |
| Houy-Durand, E | 3 |
| Tauber, C | 3 |
| Gomot, M | 3 |
| Gissot, V | 3 |
| Barantin, L | 3 |
| Lefevre, A | 3 |
| Vercouillie, J | 3 |
| Roussel, C | 3 |
| Roux, S | 5 |
| Nadal, L | 3 |
| Mavel, S | 3 |
| Laumonnier, F | 3 |
| Belzung, C | 4 |
| Chalon, S | 4 |
| Emond, P | 3 |
| Santiago-Ribeiro, MJ | 3 |
| Bonnet-Brilhault, F | 3 |
| Cipriani, C | 3 |
| Giudice, M | 3 |
| Petrone, V | 3 |
| Fanelli, M | 3 |
| Minutolo, A | 3 |
| Miele, MT | 3 |
| Toschi, N | 3 |
| Maracchioni, C | 3 |
| Siracusano, M | 3 |
| Benvenuto, A | 3 |
| Coniglio, A | 3 |
| Curatolo, P | 3 |
| Mazzone, L | 3 |
| Sandro, G | 3 |
| Garaci, E | 3 |
| Sinibaldi-Vallebona, P | 3 |
| Matteucci, C | 3 |
| Balestrieri, E | 3 |
| Xu, C | 1 |
| Zhou, Q | 1 |
| Chao, G | 1 |
| Jin, Y | 1 |
| Haratizadeh, S | 2 |
| Darvishzadeh-Mahani, F | 1 |
| Basiri, M | 2 |
| Nozari, M | 2 |
| Zhang, N | 1 |
| Wang, ST | 1 |
| Yao, L | 1 |
| Xiong, Y | 1 |
| Chen, J | 5 |
| Lv, M | 1 |
| Zhang, H | 2 |
| Li, Y | 2 |
| Luo, L | 3 |
| Wu, Q | 4 |
| Yuan, B | 3 |
| Hu, C | 3 |
| Yang, T | 5 |
| Wei, H | 2 |
| Li, T | 5 |
| Zohny, SM | 1 |
| Habib, MZ | 2 |
| Elayat, WM | 1 |
| Elhossiny, RM | 1 |
| El-Salam, MFA | 1 |
| Guerra, M | 1 |
| Medici, V | 1 |
| Weatheritt, R | 1 |
| Corvino, V | 1 |
| Palacios, D | 1 |
| Geloso, MC | 1 |
| Farini, D | 1 |
| Sette, C | 1 |
| Ahmadi, BBM | 1 |
| Afarinesh, MR | 1 |
| Jafaripour, L | 1 |
| Mirzavandi, F | 1 |
| Sabet, N | 2 |
| Aminzadeh, A | 1 |
| Heidari, M | 1 |
| Pouya, F | 1 |
| Moslemizadeh, A | 3 |
| Parizi, AS | 1 |
| Atia, AA | 1 |
| Ashour, RH | 1 |
| Zaki, MM | 1 |
| Rahman, KM | 1 |
| Ramadan, NM | 1 |
| Zahedi, E | 1 |
| Sadr, SS | 1 |
| Sanaeierad, A | 1 |
| Roghani, M | 1 |
| Shekari, MA | 1 |
| Joushi, S | 1 |
| Ebrahimi, MN | 1 |
| Taheri Zadeh, Z | 1 |
| Lin, F | 1 |
| Ahsan, AU | 1 |
| Sharma, M | 1 |
| Budhwar, M | 1 |
| Delgado-González, E | 1 |
| Durairaj, RV | 1 |
| Reyes-Haro, D | 1 |
| Martínez-Torres, A | 1 |
| Espinosa, F | 1 |
| Hameed, RA | 1 |
| Ahmed, EK | 1 |
| Mahmoud, AA | 1 |
| Atef, AA | 1 |
| Mallan, S | 1 |
| Singh, S | 2 |
| Zhang, YH | 1 |
| Wang, T | 1 |
| Li, YF | 1 |
| Deng, YN | 1 |
| He, XL | 1 |
| Wang, LJ | 1 |
| Turpin, V | 1 |
| Schaffhauser, M | 1 |
| Thabault, M | 1 |
| Aubert, A | 1 |
| Joffre, C | 1 |
| Balado, E | 1 |
| Longueville, JE | 1 |
| Francheteau, M | 1 |
| Burucoa, C | 1 |
| Pichon, M | 1 |
| Layé, S | 1 |
| Jaber, M | 1 |
| Aboul-Ela, YM | 1 |
| Ebeid, MA | 1 |
| Tarek, M | 1 |
| Sadek, DR | 1 |
| Negm, EA | 1 |
| Abdelhakam, DA | 1 |
| Lima-Castañeda, LÁ | 1 |
| Bringas, ME | 1 |
| Aguilar-Hernandez, L | 1 |
| Garcés-Ramírez, L | 1 |
| Morales-Medina, JC | 1 |
| Flores, G | 1 |
| Rostamzadeh, F | 1 |
| Rajizadeh, MA | 1 |
| Jafari, E | 1 |
| Seyedinia, SA | 1 |
| Tarahomi, P | 1 |
| Abbarin, D | 1 |
| Sedaghat, K | 1 |
| Rashidy-Pour, A | 1 |
| Yaribeygi, H | 1 |
| Vafaei, AA | 2 |
| Raise-Abdullahi, P | 2 |
| Saadat, M | 1 |
| Taherian, AA | 1 |
| Aldaghi, MR | 1 |
| Sameni, HR | 1 |
| Nakagami, Y | 1 |
| Nishi, M | 1 |
| Li, X | 3 |
| Feng, T | 1 |
| Lu, W | 1 |
| Arafat, EA | 1 |
| Shabaan, DA | 1 |
| Weinstein-Fudim, L | 1 |
| Ergaz, Z | 1 |
| Turgeman, G | 1 |
| Yanai, J | 1 |
| Szyf, M | 1 |
| Ornoy, A | 2 |
| Feng, S | 2 |
| Li, M | 1 |
| Yan, J | 1 |
| Tang, Y | 2 |
| Du, D | 2 |
| Chen, F | 2 |
| Dobrovolsky, AP | 1 |
| Gedzun, VR | 1 |
| Bogin, VI | 1 |
| Ma, D | 1 |
| Ichim, TE | 1 |
| Sukhanova, IA | 1 |
| Malyshev, AV | 1 |
| Dubynin, VA | 1 |
| Hirsch, MM | 2 |
| Staevie, GZ | 1 |
| Körbes-Rockenbach, M | 1 |
| Brum Schwingel, G | 1 |
| Rabelo, B | 2 |
| Gonçalves, MCB | 1 |
| Corrêa-Velloso, J | 1 |
| Naaldijk, Y | 1 |
| Castillo, ARG | 1 |
| Schneider, T | 5 |
| Bambini-Junior, V | 8 |
| Ulrich, H | 1 |
| Matsuo, K | 1 |
| Yabuki, Y | 2 |
| Fukunaga, K | 3 |
| de Mattos, BDS | 1 |
| Soares, MSP | 1 |
| Spohr, L | 1 |
| Pedra, NS | 1 |
| Teixeira, FC | 1 |
| de Souza, AA | 1 |
| Stefanello, FM | 1 |
| Baldissarelli, J | 1 |
| Gamaro, GD | 1 |
| Spanevello, RM | 1 |
| Lenart, J | 2 |
| Bratek, E | 1 |
| Lazarewicz, JW | 2 |
| Zieminska, E | 2 |
| Augustyniak, J | 1 |
| Chatterjee, M | 1 |
| Singh, P | 1 |
| Xu, J | 1 |
| Lombroso, PJ | 1 |
| Kurup, PK | 1 |
| Ozkul, Y | 1 |
| Taheri, S | 1 |
| Bayram, KK | 1 |
| Sener, EF | 1 |
| Mehmetbeyoglu, E | 1 |
| Öztop, DB | 1 |
| Aybuga, F | 1 |
| Tufan, E | 1 |
| Bayram, A | 1 |
| Dolu, N | 1 |
| Zararsiz, G | 1 |
| Kianmehr, L | 1 |
| Beyaz, F | 1 |
| Doganyigit, Z | 1 |
| Cuzin, F | 1 |
| Rassoulzadegan, M | 1 |
| Cheng, B | 2 |
| Wang, S | 3 |
| Liu, H | 2 |
| Zhang, X | 2 |
| Shamsi Meymandi, M | 1 |
| Vakili Shahrbabaki, S | 1 |
| Scheggi, S | 1 |
| Guzzi, F | 1 |
| Braccagni, G | 1 |
| De Montis, MG | 1 |
| Parenti, M | 1 |
| Gambarana, C | 1 |
| Chaliha, D | 1 |
| Albrecht, M | 1 |
| Vaccarezza, M | 1 |
| Takechi, R | 1 |
| Lam, V | 1 |
| Al-Salami, H | 1 |
| Mamo, J | 1 |
| Güneş, H | 1 |
| Acıpayam, C | 1 |
| Akgüngör, F | 1 |
| Kütükçü, M | 1 |
| Kasahara, Y | 1 |
| Yoshida, C | 1 |
| Nakanishi, K | 1 |
| Fukase, M | 1 |
| Suzuki, A | 1 |
| Kimura, Y | 1 |
| Farahani, M | 1 |
| Rezaei-Tavirani, M | 1 |
| Zali, A | 1 |
| Zamanian-Azodi, M | 1 |
| Wang, K | 1 |
| Li, N | 1 |
| Xu, M | 1 |
| Huang, M | 1 |
| Huang, F | 1 |
| Tong, L | 1 |
| Hassan, GA | 1 |
| Ibrahim, EA | 1 |
| Ahmed, AI | 1 |
| Kopel, J | 1 |
| Grooms, A | 1 |
| Ganapathy, V | 1 |
| Clothier, J | 1 |
| Wu, J | 1 |
| Dai, YC | 1 |
| Lan, XY | 1 |
| Zhang, HF | 1 |
| Bai, SZ | 1 |
| Hu, Y | 2 |
| Han, SP | 1 |
| Han, JS | 1 |
| Zhang, R | 3 |
| Ding, R | 1 |
| Song, Y | 1 |
| Zhang, C | 1 |
| Han, S | 1 |
| Fazzari, G | 1 |
| Zizza, M | 1 |
| Di Vito, A | 1 |
| Mandalà, M | 1 |
| Bruno, R | 1 |
| Barni, T | 1 |
| Kong, Q | 1 |
| Wang, B | 1 |
| Tian, P | 1 |
| Zhao, J | 1 |
| Chen, W | 1 |
| Wang, G | 1 |
| Gąssowska-Dobrowolska, M | 1 |
| Kolasa-Wołosiuk, A | 1 |
| Cieślik, M | 1 |
| Dominiak, A | 1 |
| Friedland, K | 1 |
| Adamczyk, A | 1 |
| Payne, M | 1 |
| Mali, I | 1 |
| McKinnell, ZE | 1 |
| Vangsness, L | 1 |
| Shrestha, TB | 1 |
| Bossmann, SH | 1 |
| Plakke, B | 1 |
| Zhai, C | 1 |
| Kang, M | 1 |
| Lan, J | 1 |
| Li, L | 1 |
| Hou, N | 1 |
| Shin, KO | 1 |
| Crumrine, DA | 1 |
| Kim, S | 1 |
| Lee, Y | 1 |
| Kim, B | 1 |
| Abuabara, K | 1 |
| Park, C | 1 |
| Uchida, Y | 1 |
| Wakefield, JS | 1 |
| Meyer, JM | 1 |
| Jeong, S | 1 |
| Park, BD | 1 |
| Park, K | 1 |
| Elias, PM | 1 |
| Thornton, AM | 1 |
| Humphrey, RM | 1 |
| Kerr, DM | 3 |
| Finn, DP | 2 |
| Roche, M | 3 |
| Giona, F | 1 |
| Pagano, J | 1 |
| Verpelli, C | 1 |
| Sala, C | 1 |
| Du, L | 1 |
| Zhao, G | 2 |
| Duan, Z | 1 |
| Li, F | 1 |
| Lim, JS | 1 |
| Lim, MY | 1 |
| Choi, Y | 1 |
| Ko, G | 1 |
| Al-Askar, M | 1 |
| Bhat, RS | 1 |
| Selim, M | 1 |
| Al-Ayadhi, L | 1 |
| El-Ansary, A | 1 |
| Cherian, KA | 1 |
| Legatt, AD | 1 |
| Cui, W | 2 |
| Zhai, Q | 1 |
| Zhang, T | 1 |
| Wen, X | 1 |
| Stadelmaier, R | 1 |
| Nasri, H | 1 |
| Deutsch, CK | 1 |
| Bauman, M | 1 |
| Hunt, A | 1 |
| Stodgell, CJ | 1 |
| Adams, J | 1 |
| Holmes, LB | 1 |
| Yamaguchi, H | 1 |
| Hara, Y | 7 |
| Ago, Y | 8 |
| Takano, E | 4 |
| Hasebe, S | 5 |
| Nakazawa, T | 3 |
| Hashimoto, H | 7 |
| Matsuda, T | 7 |
| Takuma, K | 8 |
| Veroniki, AA | 1 |
| Rios, P | 1 |
| Cogo, E | 1 |
| Straus, SE | 1 |
| Finkelstein, Y | 1 |
| Kealey, R | 1 |
| Reynen, E | 1 |
| Soobiah, C | 1 |
| Thavorn, K | 1 |
| Hutton, B | 1 |
| Hemmelgarn, BR | 1 |
| Yazdi, F | 1 |
| D'Souza, J | 1 |
| MacDonald, H | 1 |
| Tricco, AC | 1 |
| Khongrum, J | 2 |
| Wattanathorn, J | 3 |
| Higuchi, M | 2 |
| Brumback, AC | 1 |
| Ellwood, IT | 1 |
| Kjaerby, C | 1 |
| Iafrati, J | 1 |
| Robinson, S | 1 |
| Lee, AT | 1 |
| Patel, T | 1 |
| Nagaraj, S | 1 |
| Davatolhagh, F | 1 |
| Sohal, VS | 2 |
| Servadio, M | 2 |
| Manduca, A | 1 |
| Melancia, F | 2 |
| Leboffe, L | 1 |
| Schiavi, S | 4 |
| Campolongo, P | 2 |
| Palmery, M | 2 |
| Ascenzi, P | 1 |
| di Masi, A | 1 |
| Trezza, V | 4 |
| Wu, H | 1 |
| Zhang, Q | 1 |
| Gao, J | 3 |
| Sun, C | 2 |
| Xia, W | 2 |
| Cao, Y | 3 |
| Hao, Y | 2 |
| Wu, L | 3 |
| Zhou, J | 2 |
| Ren, J | 2 |
| Sun, S | 1 |
| An, X | 1 |
| Zhang, K | 1 |
| Qian, Z | 1 |
| Shi, M | 1 |
| Qiao, Y | 1 |
| Cezar, LC | 1 |
| Kirsten, TB | 1 |
| da Fonseca, CCN | 1 |
| de Lima, APN | 1 |
| Bernardi, MM | 1 |
| Felicio, LF | 1 |
| Ripoli, C | 1 |
| Pinna, AP | 1 |
| Podda, F | 1 |
| Zanni, R | 1 |
| Tronci, MG | 1 |
| Nurchi, AM | 1 |
| Della-Flora Nunes, G | 2 |
| Nunes, W | 1 |
| Margis, R | 1 |
| Hennessey, T | 1 |
| Andari, E | 1 |
| Rainnie, DG | 1 |
| Gupta, T | 1 |
| Marquart, GD | 1 |
| Horstick, EJ | 1 |
| Tabor, KM | 1 |
| Pajevic, S | 1 |
| Burgess, HA | 1 |
| Khalaj, R | 1 |
| Zare, M | 1 |
| Cartocci, V | 2 |
| Pallottini, V | 2 |
| Baronio, D | 2 |
| Castro, K | 2 |
| Mendes-da-Cruz, DA | 1 |
| Savino, W | 1 |
| Eissa, N | 1 |
| Jayaprakash, P | 1 |
| Azimullah, S | 1 |
| Ojha, SK | 1 |
| Al-Houqani, M | 1 |
| Jalal, FY | 1 |
| Łażewska, D | 1 |
| Kieć-Kononowicz, K | 1 |
| Sadek, B | 1 |
| Tonini, C | 1 |
| Di Pippo, T | 1 |
| Vuono, F | 1 |
| Marino, M | 1 |
| Win-Shwe, TT | 1 |
| Nway, NC | 1 |
| Imai, M | 1 |
| Lwin, TT | 1 |
| Mar, O | 1 |
| Watanabe, H | 1 |
| Kawase, H | 1 |
| Naito, M | 1 |
| Tsukada, S | 1 |
| Kasai, A | 1 |
| Mishina, T | 1 |
| Kouji, H | 1 |
| Bailly, Y | 1 |
| Bossu, JL | 2 |
| Horton-Sparks, K | 1 |
| Hull, V | 1 |
| Li, RW | 1 |
| Martínez-Cerdeño, V | 1 |
| Bronzuoli, MR | 1 |
| Facchinetti, R | 1 |
| Ingrassia, D | 1 |
| Sarvadio, M | 1 |
| Steardo, L | 1 |
| Verkhratsky, A | 1 |
| Scuderi, C | 1 |
| Mirza, R | 1 |
| Sharma, B | 3 |
| Xiang, Z | 1 |
| Jia, Y | 1 |
| He, X | 1 |
| Wang, L | 1 |
| Spisák, T | 1 |
| Román, V | 1 |
| Papp, E | 1 |
| Kedves, R | 1 |
| Sághy, K | 1 |
| Csölle, CK | 1 |
| Varga, A | 1 |
| Gajári, D | 1 |
| Nyitrai, G | 1 |
| Spisák, Z | 1 |
| Kincses, ZT | 1 |
| Lévay, G | 1 |
| Lendvai, B | 1 |
| Czurkó, A | 1 |
| Zheng, W | 1 |
| Chen, D | 1 |
| Grønborg, TK | 1 |
| Sørensen, MJ | 1 |
| Schendel, D | 1 |
| Parner, ET | 1 |
| Pedersen, LH | 1 |
| Vestergaard, M | 1 |
| Meador, KJ | 2 |
| Loring, DW | 2 |
| Downey, L | 1 |
| Conboy, M | 1 |
| Oguchi-Katayama, A | 1 |
| Monma, A | 1 |
| Sekino, Y | 1 |
| Moriguchi, T | 1 |
| Sato, K | 1 |
| Selim, ME | 2 |
| Al-Ayadhi, LY | 2 |
| Bachmann, CJ | 1 |
| Manthey, T | 1 |
| Kamp-Becker, I | 1 |
| Glaeske, G | 1 |
| Hoffmann, F | 1 |
| Kim, JE | 1 |
| Shin, MS | 1 |
| Seo, TB | 1 |
| Ji, ES | 1 |
| Baek, SS | 1 |
| Lee, SJ | 1 |
| Park, JK | 1 |
| Kim, CJ | 1 |
| Edalatmanesh, MA | 1 |
| Nikfarjam, H | 1 |
| Vafaee, F | 1 |
| Moghadas, M | 1 |
| Wang, CC | 2 |
| Lin, HC | 3 |
| Chan, YH | 2 |
| Gean, PW | 2 |
| Yang, YK | 1 |
| Chen, PS | 3 |
| Moriguchi, S | 2 |
| Mao, PJ | 1 |
| Hong, LJ | 1 |
| Lu, YM | 2 |
| Wang, R | 1 |
| Ahmed, MM | 1 |
| Liao, MH | 2 |
| Huang, JY | 2 |
| Zhang, RT | 1 |
| Zhou, TY | 1 |
| Long, S | 2 |
| Han, F | 2 |
| Wood, A | 1 |
| Kim, KC | 4 |
| Lee, DK | 1 |
| Go, HS | 2 |
| Kim, P | 2 |
| Choi, CS | 4 |
| Kim, JW | 3 |
| Jeon, SJ | 1 |
| Song, MR | 1 |
| Shin, CY | 4 |
| Ali, EH | 2 |
| Elgoly, AH | 2 |
| Ward, CS | 1 |
| Taktak, A | 1 |
| Acar, B | 1 |
| Gür, G | 1 |
| Tiryaki, T | 1 |
| Albayrak, A | 1 |
| Çakar, N | 1 |
| Almeida, LE | 1 |
| Roby, CD | 1 |
| Krueger, BK | 1 |
| Tyzio, R | 1 |
| Nardou, R | 1 |
| Tsintsadze, T | 1 |
| Shahrokhi, A | 1 |
| Khalilov, I | 1 |
| Tsintsadze, V | 1 |
| Brouchoud, C | 1 |
| Chazal, G | 1 |
| Lemonnier, E | 1 |
| Lozovaya, N | 1 |
| Burnashev, N | 1 |
| Engineer, CT | 1 |
| Centanni, TM | 1 |
| Im, KW | 1 |
| Borland, MS | 1 |
| Moreno, NA | 1 |
| Carraway, RS | 1 |
| Wilson, LG | 1 |
| Kilgard, MP | 2 |
| Smith, V | 1 |
| Brown, N | 1 |
| Pragnya, B | 1 |
| Kameshwari, JS | 1 |
| Veeresh, B | 2 |
| Baxter, P | 1 |
| Sabers, A | 1 |
| Bertelsen, FC | 1 |
| Scheel-Krüger, J | 1 |
| Nyengaard, JR | 1 |
| Møller, A | 1 |
| Seung, H | 1 |
| Kwon, KJ | 1 |
| Ko, MJ | 1 |
| Lee, EJ | 1 |
| Oh, HA | 1 |
| Gonzales, EL | 1 |
| You, JS | 1 |
| Choi, DH | 1 |
| Lee, J | 1 |
| Han, SH | 2 |
| Yang, SM | 1 |
| Cheong, JH | 3 |
| Bahn, GH | 1 |
| Kataoka, S | 2 |
| Kawanai, T | 2 |
| Maeda, Y | 2 |
| Watanabe, R | 2 |
| Hayata-Takano, A | 1 |
| Zanatta, G | 1 |
| Della Flora Nunes, G | 1 |
| Mueller de Melo, G | 1 |
| Michels, M | 1 |
| Nogueira Freire, V | 1 |
| Ryu, JH | 1 |
| Hegazy, HG | 1 |
| Trivisano, M | 1 |
| Specchio, N | 1 |
| Vigevano, F | 1 |
| Raza, S | 2 |
| Harker, A | 2 |
| Richards, S | 1 |
| Kolb, B | 2 |
| Gibb, R | 2 |
| Gonchoroski, T | 1 |
| de Melo, GM | 1 |
| Abd-Elhakim, YM | 1 |
| Nicolini, C | 1 |
| Ahn, Y | 1 |
| Michalski, B | 1 |
| Rho, JM | 1 |
| Fahnestock, M | 1 |
| Braida, D | 1 |
| Guerini, FR | 1 |
| Ponzoni, L | 1 |
| Corradini, I | 1 |
| De Astis, S | 1 |
| Pattini, L | 1 |
| Bolognesi, E | 1 |
| Benfante, R | 1 |
| Fornasari, D | 1 |
| Chiappedi, M | 1 |
| Ghezzo, A | 1 |
| Clerici, M | 1 |
| Matteoli, M | 1 |
| Sala, M | 1 |
| Al-Amin, MM | 1 |
| Rahman, MM | 1 |
| Khan, FR | 1 |
| Zaman, F | 1 |
| Mahmud Reza, H | 1 |
| Lazic, SE | 1 |
| Codagnone, MG | 1 |
| Podestá, MF | 1 |
| Uccelli, NA | 1 |
| Reinés, A | 1 |
| Katashiba, K | 2 |
| Taruta, A | 3 |
| Higashino, K | 1 |
| Liang, S | 2 |
| Cheaha, D | 2 |
| Bumrungsri, S | 1 |
| Chatpun, S | 1 |
| Kumarnsit, E | 2 |
| Kaushik, G | 2 |
| Thomas, MA | 2 |
| Aho, KA | 1 |
| Olde Loohuis, NF | 1 |
| Kole, K | 1 |
| Glennon, JC | 1 |
| Karel, P | 1 |
| Van der Borg, G | 1 |
| Van Gemert, Y | 1 |
| Van den Bosch, D | 1 |
| Meinhardt, J | 1 |
| Kos, A | 1 |
| Shahabipour, F | 1 |
| Tiesinga, P | 1 |
| van Bokhoven, H | 1 |
| Martens, GJ | 1 |
| Kaplan, BB | 1 |
| Homberg, JR | 1 |
| Aschrafi, A | 1 |
| Luongo, FJ | 1 |
| Horn, ME | 1 |
| Yasue, M | 1 |
| Nakagami, A | 1 |
| Banno, T | 1 |
| Nakagaki, K | 1 |
| Ichinohe, N | 1 |
| Kawai, N | 1 |
| Himmler, BT | 1 |
| Himmler, SM | 1 |
| Pellis, SM | 1 |
| Qin, L | 1 |
| Dai, X | 1 |
| Kumar, H | 2 |
| Sun, H | 1 |
| Yang, F | 1 |
| Zhang, F | 1 |
| Onaka, Y | 2 |
| Solignac, I | 1 |
| Morakotsriwan, N | 1 |
| Kirisattayakul, W | 1 |
| Chaisiwamongkol, K | 1 |
| Yang, EJ | 1 |
| Ahn, S | 1 |
| Lee, K | 1 |
| Mahmood, U | 2 |
| Kim, HS | 1 |
| Wang, P | 1 |
| Wei, Z | 1 |
| Inoue, A | 1 |
| Wang, HJ | 1 |
| Shen, H | 1 |
| Liu, ZR | 1 |
| Wang, ZM | 1 |
| Li, D | 1 |
| Tao, RR | 1 |
| Cui, TT | 1 |
| Xia, Y | 1 |
| Wu, HF | 1 |
| Chen, YJ | 1 |
| Lee, CW | 1 |
| Chen, IT | 1 |
| Gilmartin, A | 1 |
| Bertolino, B | 1 |
| Crupi, R | 1 |
| Impellizzeri, D | 1 |
| Bruschetta, G | 1 |
| Cordaro, M | 1 |
| Siracusa, R | 1 |
| Esposito, E | 1 |
| Cuzzocrea, S | 1 |
| Ha, S | 1 |
| Park, H | 1 |
| Ra, JC | 1 |
| Suh, YH | 1 |
| Chang, KA | 1 |
| Yadav, S | 1 |
| Tiwari, V | 1 |
| Singh, M | 1 |
| Yadav, RK | 1 |
| Roy, S | 1 |
| Devi, U | 1 |
| Gautam, S | 1 |
| Rawat, JK | 1 |
| Ansari, MN | 1 |
| Saeedan, AS | 1 |
| Prakash, A | 1 |
| Saraf, SA | 1 |
| Kaithwas, G | 1 |
| Murawski, NJ | 2 |
| Brown, KL | 2 |
| Stanton, ME | 2 |
| Snow, WM | 1 |
| Hartle, K | 1 |
| Ivanco, TL | 1 |
| Rout, UK | 1 |
| Clausen, P | 1 |
| Kuwagata, M | 1 |
| Ogawa, T | 1 |
| Shioda, S | 1 |
| Nagata, T | 1 |
| Narita, M | 3 |
| Oyabu, A | 2 |
| Imura, Y | 2 |
| Kamada, N | 1 |
| Yokoyama, T | 1 |
| Tano, K | 1 |
| Uchida, A | 2 |
| Narita, N | 3 |
| Dufour-Rainfray, D | 1 |
| Vourc'h, P | 1 |
| Le Guisquet, AM | 1 |
| Garreau, L | 1 |
| Ternant, D | 1 |
| Bodard, S | 1 |
| Jaumain, E | 1 |
| Gulhan, Z | 1 |
| Andres, CR | 1 |
| Guilloteau, D | 1 |
| Yochum, CL | 1 |
| Bhattacharya, P | 1 |
| Patti, L | 1 |
| Mirochnitchenko, O | 1 |
| Wagner, GC | 2 |
| Veenstra-VanderWeele, J | 1 |
| Roullet, FI | 1 |
| Wollaston, L | 1 |
| Decatanzaro, D | 1 |
| Foster, JA | 1 |
| Chomiak, T | 1 |
| Karnik, V | 1 |
| Block, E | 1 |
| Hu, B | 1 |
| Yasuhara, A | 1 |
| Vamecq, J | 1 |
| Joncquel-Chevalier Curt, M | 1 |
| Mention-Mulliez, K | 1 |
| Dobbelaere, D | 1 |
| Briand, G | 1 |
| Gandal, MJ | 2 |
| Edgar, JC | 1 |
| Ehrlichman, RS | 1 |
| Mehta, M | 1 |
| Roberts, TP | 1 |
| Siegel, SJ | 2 |
| Yang, SI | 1 |
| Ko, KH | 1 |
| Bos, MJ | 1 |
| de Weerd, AW | 1 |
| Hagebeuk, EE | 1 |
| Tashiro, Y | 1 |
| Brennan, SO | 1 |
| Oliver, J | 1 |
| Davis, RL | 1 |
| Lukose, R | 1 |
| Schmidt, E | 1 |
| Wolski, TP | 1 |
| Kulesza, RJ | 1 |
| Rodrigues, L | 1 |
| Behr, GA | 1 |
| Moreira, JC | 1 |
| Banji, D | 1 |
| Banji, OJ | 1 |
| Abbagoni, S | 1 |
| Hayath, MS | 1 |
| Kambam, S | 1 |
| Chiluka, VL | 1 |
| Mehta, MV | 1 |
| Sandhya, T | 1 |
| Sowjanya, J | 1 |
| Reynolds, S | 1 |
| Millette, A | 1 |
| Devine, DP | 1 |
| Bristot Silvestrin, R | 1 |
| Galland, F | 1 |
| Daniele Bobermim, L | 1 |
| Quincozes-Santos, A | 1 |
| Torres Abib, R | 1 |
| Zanotto, C | 1 |
| Batassini, C | 1 |
| Brolese, G | 1 |
| Gonçalves, CA | 1 |
| Banerjee, A | 1 |
| García-Oscos, F | 1 |
| Roychowdhury, S | 1 |
| Galindo, LC | 1 |
| Hall, S | 1 |
| Atzori, M | 1 |
| Rugino, TA | 1 |
| Samsock, TC | 1 |
| Kato, M | 1 |
| Tazoe, M | 1 |
| Miyazaki, K | 1 |
| Okado, N | 1 |
| Ribeiro, KM | 1 |
| Assumpção, FB | 1 |
| Valente, KD | 1 |
| Przewłocki, R | 4 |
| Hellings, JA | 1 |
| Nickel, EJ | 1 |
| Weckbaugh, M | 1 |
| McCarter, K | 1 |
| Mosier, M | 1 |
| Schroeder, SR | 1 |
| Alsdorf, R | 1 |
| Wyszynski, DF | 1 |
| Rana, M | 1 |
| Khanzode, L | 1 |
| Karnik, N | 1 |
| Saxena, K | 1 |
| Chang, K | 1 |
| Steiner, H | 1 |
| Turczak, J | 1 |
| Hollander, E | 3 |
| Soorya, L | 2 |
| Wasserman, S | 2 |
| Esposito, K | 2 |
| Chaplin, W | 2 |
| Anagnostou, E | 2 |
| Chez, MG | 1 |
| Chang, M | 1 |
| Krasne, V | 1 |
| Coughlan, C | 1 |
| Kominsky, M | 1 |
| Schwartz, A | 1 |
| Genton, P | 1 |
| Semah, F | 1 |
| Trinka, E | 1 |
| Reuhl, KR | 1 |
| Cheh, M | 1 |
| McRae, P | 1 |
| Halladay, AK | 1 |
| Peloso, E | 1 |
| Rodier, P | 1 |
| Tsujino, N | 2 |
| Nakatani, Y | 2 |
| Seki, Y | 2 |
| Nakasato, A | 2 |
| Nakamura, M | 1 |
| Sugawara, M | 1 |
| Arita, H | 2 |
| Ivanov, I | 1 |
| Klein, M | 1 |
| Green, WH | 1 |
| Coffey, B | 1 |
| Ziòłkowska, B | 1 |
| Gieryk, A | 1 |
| Tyminska, A | 1 |
| Markram, K | 1 |
| Rinaldi, T | 2 |
| La Mendola, D | 1 |
| Sandi, C | 1 |
| Markram, H | 2 |
| Silberberg, G | 1 |
| Carrim, ZI | 1 |
| McKay, L | 1 |
| Sidiki, SS | 1 |
| Lavy, TE | 1 |
| Umino, M | 1 |
| Roman, A | 1 |
| Basta-Kaim, A | 1 |
| Kubera, M | 1 |
| Budziszewska, B | 1 |
| Schneider, K | 1 |
| Christianson, AL | 1 |
| Chesler, N | 1 |
| Kromberg, JG | 1 |
| Plioplys, AV | 1 |
| Brasić, JR | 1 |
| Barnett, JY | 1 |
| Childs, JA | 1 |
| Blair, JL | 1 |
| Williams, PG | 1 |
| Hersh, JH | 2 |
| Damore, J | 1 |
| Stine, J | 1 |
| Brody, L | 1 |
| Hilty, DM | 1 |
| Rodriguez, GD | 1 |
| Hales, RE | 1 |
| Williams, G | 1 |
| King, J | 1 |
| Cunningham, M | 1 |
| Stephan, M | 1 |
| Kerr, B | 1 |
| Dolgoff-Kaspar, R | 1 |
| Cartwright, C | 1 |
| Rawitt, R | 1 |
| Novotny, S | 1 |
| Bescoby-Chambers, N | 1 |
| Forster, P | 1 |
| Bates, G | 1 |
| Sovner, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Rett Syndrome, MECP2 Duplication, and Rett-Related Disorders Consortium, Rare Disease Clinical Research Network: Neurophysiologic Correlates[NCT03077308] | 185 participants (Actual) | Observational | 2017-01-02 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for valproic acid and Autism
| Article | Year |
|---|---|
Critical Evaluation of Valproic Acid-Induced Rodent Models of Autism: Current and Future Perspectives.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Fema | 2022 |
A Systematic Review of the Valproic-Acid-Induced Rodent Model of Autism.
Topics: Animals; Anticonvulsants; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Humans; Roden | 2020 |
Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis.
Topics: Anticonvulsants; Autistic Disorder; Bayes Theorem; Breast Feeding; Carbamazepine; Child; Epilepsy; F | 2017 |
RDoC-based categorization of amygdala functions and its implications in autism.
Topics: Amygdala; Autistic Disorder; Cognition; Humans; National Institute of Mental Health (U.S.); Oxytocin | 2018 |
Neuroimmune Alterations in Autism: A Translational Analysis Focusing on the Animal Model of Autism Induced by Prenatal Exposure to Valproic Acid.
Topics: Animals; Autistic Disorder; Disease Models, Animal; Enzyme Inhibitors; Female; Humans; Mice; Neuroim | 2018 |
[The valproate model of autism].
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Disease Models, Animal; Female; Humans; Mice; | 2019 |
Valproic acid in pregnancy: how much are we endangering the embryo and fetus?
Topics: Abnormalities, Drug-Induced; Adolescent; Animals; Anticonvulsants; Autistic Disorder; Child; Child D | 2009 |
Teratogenicity of sodium valproate.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Animals; Autistic Disorder; Cleft Lip; | 2005 |
Divalproex sodium in the treatment of pediatric psychiatric disorders.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Autistic Diso | 2005 |
Valproic acid in epilepsy : pregnancy-related issues.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Autistic Disorder; Epilepsy; Female; Humans; Infant, N | 2006 |
5 trials available for valproic acid and Autism
| Article | Year |
|---|---|
Levetiracetam in autistic children: an open-label study.
Topics: Aggression; Anticonvulsants; Autistic Disorder; Cetirizine; Child; Child Behavior Disorders; Child, | 2002 |
The overt aggression scale for rating aggression in outpatient youth with autistic disorder: preliminary findings.
Topics: Adolescent; Adult; Aggression; Ambulatory Care; Autistic Disorder; Child; Double-Blind Method; Femal | 2005 |
Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder.
Topics: Adolescent; Adult; Anticonvulsants; Autistic Disorder; Child; Child, Preschool; Double-Blind Method; | 2006 |
Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder.
Topics: Antidepressive Agents, Second-Generation; Antimanic Agents; Autistic Disorder; Child; Double-Blind M | 2006 |
An open trial of divalproex sodium in autism spectrum disorders.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Antipsychotic Agents; Asperger Syndrome; Autistic D | 2001 |
247 other studies available for valproic acid and Autism
| Article | Year |
|---|---|
Correlation among gut microbiota, fecal metabolites and autism-like behavior in an adolescent valproic acid-induced rat autism model.
Topics: Animals; Autistic Disorder; Disease Models, Animal; Feces; Female; Gastrointestinal Microbiome; Groo | 2022 |
Beyond Genes: Germline Disruption in the Etiology of Autism Spectrum Disorders.
Topics: Anesthetics, Inhalation; Autism Spectrum Disorder; Autistic Disorder; Germ Cells; Humans; Valproic A | 2022 |
Assessment of behavioral, morphological and electrophysiological changes in prenatal and postnatal valproate induced rat models of autism spectrum disorder.
Topics: Animals; Anticonvulsants; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Brain; Dise | 2021 |
Sex-specific differences in the gut microbiota and fecal metabolites in an adolescent valproic acid-induced rat autism model.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Brain-Gut Axis; Female; Gastrointestinal Micro | 2021 |
Novel role of peroxisome proliferator activated receptor-α in valproic acid rat model of autism: Mechanistic study of risperidone and metformin monotherapy versus combination.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Fema | 2022 |
Early postnatal handling alters social behavior, learning, and memory of pre- and postnatal VPA-induced rat models of autism in a context-based manner.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Fema | 2022 |
[Epigenetic mechanisms involved in the genesis of autism].
Topics: Autistic Disorder; DNA Methylation; Epigenesis, Genetic; Humans; Valproic Acid | 2022 |
Degraded cortical temporal processing in the valproic acid-induced rat model of autism.
Topics: Animals; Auditory Perception; Autism Spectrum Disorder; Autistic Disorder; Disease Models, Animal; N | 2022 |
Alterations of the Hippocampal Networks in Valproic Acid-Induced Rat Autism Model.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Disease Models, Animal; Female; Hippocampus; M | 2022 |
Mild Hypophagia and Associated Changes in Feeding-Related Gene Expression and c-Fos Immunoreactivity in Adult Male Rats with Sodium Valproate-Induced Autism.
Topics: Animals; Autistic Disorder; Body Weight; Eating; Gene Expression; Male; Proto-Oncogene Proteins c-fo | 2022 |
The GABAB receptor agonist STX209 reverses the autism‑like behaviour in an animal model of autism induced by prenatal exposure to valproic acid.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Fema | 2022 |
Postweaning positive modulation of α5GABAA receptors improves autism-like features in prenatal valproate rat model in a sex-specific manner.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Calcium; Disease Models, Ani | 2022 |
Sumac and gallic acid-loaded nanophytosomes ameliorate hippocampal oxidative stress via regulation of Nrf2/Keap1 pathway in autistic rats.
Topics: Animals; Antioxidants; Autistic Disorder; Female; Gallic Acid; Glutathione; Glutathione Peroxidase; | 2022 |
Human forebrain organoids reveal connections between valproic acid exposure and autism risk.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Chloride Channels; Disease Models, Animal; Hum | 2022 |
Autism-like symptoms by exposure to air pollution and valproic acid-induced in male rats.
Topics: Air Pollutants; Air Pollution; Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Anima | 2022 |
Size anomaly and alteration of GABAergic enzymes expressions in cerebellum of a valproic acid mouse model of autism.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Cerebellum; Disease Models, Animal; Female; ga | 2022 |
Postnatal baicalin ameliorates behavioral and neurochemical alterations in valproic acid-induced rodent model of autism: The possible implication of sirtuin-1/mitofusin-2/ Bcl-2 pathway.
Topics: Animals; Antioxidants; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Disease Models | 2022 |
Resveratrol Prevents Cytoarchitectural and Interneuronal Alterations in the Valproic Acid Rat Model of Autism.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Disease Models, Animal; Female; Interneurons; | 2022 |
Juvenile handling rescues autism-related effects of prenatal exposure to valproic acid.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Fema | 2022 |
Histamine H3 receptor antagonist, ciproxifan, alleviates cognition and synaptic plasticity alterations in a valproic acid-induced animal model of autism.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Cognition; Disease Models, Animal; Female; His | 2022 |
Vitamin A supplementation ameliorates prenatal valproic acid-induced autism-like behaviors in rats.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Dietary Supplements; Disease Models, Animal; F | 2022 |
Prenatal reduction of E14.5 embryonically fate-mapped pyramidal neurons in a mouse model of autism.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Disease Models, Animal; Female; Humans; Mice; | 2022 |
Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability.
Topics: Anticonvulsants; Autism Spectrum Disorder; Autistic Disorder; Carbamazepine; Child; Cohort Studies; | 2022 |
Prenatal exposure to valproic acid alters Reelin, NGF expressing neuron architecture and impairs social interaction in their autistic-like phenotype male offspring.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Caspase 3; Disease Models, A | 2022 |
Congenitally underdeveloped intestine drives autism-related gut microbiota and behavior.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Dysbiosis; Gastrointestinal Diseases; Gastroin | 2022 |
TCHis mitigate oxidative stress and improve abnormal behavior in a prenatal valproic acid-exposed rat model of autism.
Topics: Animals; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Female; Humans; Hydroxyethylru | 2022 |
Modifications of Behavior and Inflammation in Mice Following Transplant with Fecal Microbiota from Children with Autism.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Child; Disease Models, Animal; Female; Humans; | 2022 |
Changes of cerebellar cortex in a valproic acid-induced rat model of autism.
Topics: Animals; Autistic Disorder; Cerebellar Cortex; Cerebellum; Disease Models, Animal; Female; Humans; M | 2022 |
Alterations in the intrinsic discharge activity of CA1 pyramidal neurons associated with possible changes in the NADPH diaphorase activity in a rat model of autism induced by prenatal exposure to valproic acid.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Disease Models, Animal; Female; NADPH Dehydrog | 2022 |
Early-onset of social communication and locomotion activity in F2 pups of a valproic acid-induced mouse model of autism.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Communication; Disease Model | 2022 |
Attenuation of Autism-like Behaviors by an Anthocyanin-Rich Extract from Portuguese Blueberries via Microbiota-Gut-Brain Axis Modulation in a Valproic Acid Mouse Model.
Topics: Animals; Anthocyanins; Autism Spectrum Disorder; Autistic Disorder; Blueberry Plants; Brain-Gut Axis | 2022 |
Effects of arginine vasopressin on the transcriptome of prefrontal cortex in autistic rat model.
Topics: Animals; Arginine Vasopressin; Autistic Disorder; Disease Models, Animal; Prefrontal Cortex; Rats; T | 2022 |
Rescue of social deficits by early-life melatonin supplementation through modulation of gut microbiota in a murine model of autism.
Topics: Akkermansia; Animals; Autism Spectrum Disorder; Autistic Disorder; Dietary Supplements; Disease Mode | 2022 |
Rescue of social deficits by early-life melatonin supplementation through modulation of gut microbiota in a murine model of autism.
Topics: Akkermansia; Animals; Autism Spectrum Disorder; Autistic Disorder; Dietary Supplements; Disease Mode | 2022 |
Rescue of social deficits by early-life melatonin supplementation through modulation of gut microbiota in a murine model of autism.
Topics: Akkermansia; Animals; Autism Spectrum Disorder; Autistic Disorder; Dietary Supplements; Disease Mode | 2022 |
Rescue of social deficits by early-life melatonin supplementation through modulation of gut microbiota in a murine model of autism.
Topics: Akkermansia; Animals; Autism Spectrum Disorder; Autistic Disorder; Dietary Supplements; Disease Mode | 2022 |
Rescue of social deficits by early-life melatonin supplementation through modulation of gut microbiota in a murine model of autism.
Topics: Akkermansia; Animals; Autism Spectrum Disorder; Autistic Disorder; Dietary Supplements; Disease Mode | 2022 |
Rescue of social deficits by early-life melatonin supplementation through modulation of gut microbiota in a murine model of autism.
Topics: Akkermansia; Animals; Autism Spectrum Disorder; Autistic Disorder; Dietary Supplements; Disease Mode | 2022 |
Rescue of social deficits by early-life melatonin supplementation through modulation of gut microbiota in a murine model of autism.
Topics: Akkermansia; Animals; Autism Spectrum Disorder; Autistic Disorder; Dietary Supplements; Disease Mode | 2022 |
Rescue of social deficits by early-life melatonin supplementation through modulation of gut microbiota in a murine model of autism.
Topics: Akkermansia; Animals; Autism Spectrum Disorder; Autistic Disorder; Dietary Supplements; Disease Mode | 2022 |
Rescue of social deficits by early-life melatonin supplementation through modulation of gut microbiota in a murine model of autism.
Topics: Akkermansia; Animals; Autism Spectrum Disorder; Autistic Disorder; Dietary Supplements; Disease Mode | 2022 |
Differential Alterations in Striatal Direct and Indirect Pathways Mediate Two Autism-like Behaviors in Valproate-Exposed Mice.
Topics: Animals; Autistic Disorder; Male; Mice; Social Behavior; Valproic Acid; Ventral Striatum | 2022 |
Differential Alterations in Striatal Direct and Indirect Pathways Mediate Two Autism-like Behaviors in Valproate-Exposed Mice.
Topics: Animals; Autistic Disorder; Male; Mice; Social Behavior; Valproic Acid; Ventral Striatum | 2022 |
Differential Alterations in Striatal Direct and Indirect Pathways Mediate Two Autism-like Behaviors in Valproate-Exposed Mice.
Topics: Animals; Autistic Disorder; Male; Mice; Social Behavior; Valproic Acid; Ventral Striatum | 2022 |
Differential Alterations in Striatal Direct and Indirect Pathways Mediate Two Autism-like Behaviors in Valproate-Exposed Mice.
Topics: Animals; Autistic Disorder; Male; Mice; Social Behavior; Valproic Acid; Ventral Striatum | 2022 |
Differential Alterations in Striatal Direct and Indirect Pathways Mediate Two Autism-like Behaviors in Valproate-Exposed Mice.
Topics: Animals; Autistic Disorder; Male; Mice; Social Behavior; Valproic Acid; Ventral Striatum | 2022 |
Differential Alterations in Striatal Direct and Indirect Pathways Mediate Two Autism-like Behaviors in Valproate-Exposed Mice.
Topics: Animals; Autistic Disorder; Male; Mice; Social Behavior; Valproic Acid; Ventral Striatum | 2022 |
Differential Alterations in Striatal Direct and Indirect Pathways Mediate Two Autism-like Behaviors in Valproate-Exposed Mice.
Topics: Animals; Autistic Disorder; Male; Mice; Social Behavior; Valproic Acid; Ventral Striatum | 2022 |
Differential Alterations in Striatal Direct and Indirect Pathways Mediate Two Autism-like Behaviors in Valproate-Exposed Mice.
Topics: Animals; Autistic Disorder; Male; Mice; Social Behavior; Valproic Acid; Ventral Striatum | 2022 |
Differential Alterations in Striatal Direct and Indirect Pathways Mediate Two Autism-like Behaviors in Valproate-Exposed Mice.
Topics: Animals; Autistic Disorder; Male; Mice; Social Behavior; Valproic Acid; Ventral Striatum | 2022 |
Glutamatergic synapse in autism: a complex story for a complex disorder.
Topics: Adolescent; Adult; Animals; Autism Spectrum Disorder; Autistic Disorder; Brain; Child; Female; Gluta | 2023 |
Glutamatergic synapse in autism: a complex story for a complex disorder.
Topics: Adolescent; Adult; Animals; Autism Spectrum Disorder; Autistic Disorder; Brain; Child; Female; Gluta | 2023 |
Glutamatergic synapse in autism: a complex story for a complex disorder.
Topics: Adolescent; Adult; Animals; Autism Spectrum Disorder; Autistic Disorder; Brain; Child; Female; Gluta | 2023 |
Glutamatergic synapse in autism: a complex story for a complex disorder.
Topics: Adolescent; Adult; Animals; Autism Spectrum Disorder; Autistic Disorder; Brain; Child; Female; Gluta | 2023 |
Glutamatergic synapse in autism: a complex story for a complex disorder.
Topics: Adolescent; Adult; Animals; Autism Spectrum Disorder; Autistic Disorder; Brain; Child; Female; Gluta | 2023 |
Glutamatergic synapse in autism: a complex story for a complex disorder.
Topics: Adolescent; Adult; Animals; Autism Spectrum Disorder; Autistic Disorder; Brain; Child; Female; Gluta | 2023 |
Glutamatergic synapse in autism: a complex story for a complex disorder.
Topics: Adolescent; Adult; Animals; Autism Spectrum Disorder; Autistic Disorder; Brain; Child; Female; Gluta | 2023 |
Glutamatergic synapse in autism: a complex story for a complex disorder.
Topics: Adolescent; Adult; Animals; Autism Spectrum Disorder; Autistic Disorder; Brain; Child; Female; Gluta | 2023 |
Glutamatergic synapse in autism: a complex story for a complex disorder.
Topics: Adolescent; Adult; Animals; Autism Spectrum Disorder; Autistic Disorder; Brain; Child; Female; Gluta | 2023 |
Modulation of human endogenous retroviruses and cytokines expression in peripheral blood mononuclear cells from autistic children and their parents.
Topics: Autism Spectrum Disorder; Autistic Disorder; Child; Cytokines; Endogenous Retroviruses; Humans; Inte | 2022 |
Modulation of human endogenous retroviruses and cytokines expression in peripheral blood mononuclear cells from autistic children and their parents.
Topics: Autism Spectrum Disorder; Autistic Disorder; Child; Cytokines; Endogenous Retroviruses; Humans; Inte | 2022 |
Modulation of human endogenous retroviruses and cytokines expression in peripheral blood mononuclear cells from autistic children and their parents.
Topics: Autism Spectrum Disorder; Autistic Disorder; Child; Cytokines; Endogenous Retroviruses; Humans; Inte | 2022 |
Modulation of human endogenous retroviruses and cytokines expression in peripheral blood mononuclear cells from autistic children and their parents.
Topics: Autism Spectrum Disorder; Autistic Disorder; Child; Cytokines; Endogenous Retroviruses; Humans; Inte | 2022 |
Effects of different doses of lithium on the central nervous system in the rat valproic acid model of autism.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Hippocampus; Lithium; Lithium Compounds; Rats; | 2023 |
The effects of postnatal erythropoietin and nano-erythropoietin on behavioral alterations by mediating K-Cl co-transporter 2 in the valproic acid-induced rat model of autism.
Topics: Animals; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Erythropoietin; Female; gamma- | 2023 |
Inhalation of Cananga odorata essential oil relieves anxiety behaviors in autism-like rats via regulation of serotonin and dopamine metabolism.
Topics: Animals; Anxiety; Autistic Disorder; Cananga; Disease Models, Animal; Dopamine; Female; Oils, Volati | 2023 |
Thymol improves autism-like behaviour in VPA-induced ASD rats through the Pin1/p38 MAPK pathway.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Disease Models, Animal; Female; Humans; Inflam | 2023 |
Prenatally VPA exposure is likely to cause autistic-like behavior in the rats offspring via TREM2 down-regulation to affect the microglial activation and synapse alterations.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Down | 2023 |
Astrocyte responses to postnatal erythropoietin and nano-erythropoietin treatments in a valproic acid-induced animal model of autism.
Topics: Animals; Astrocytes; Autistic Disorder; Behavior, Animal; CA1 Region, Hippocampal; Disease Models, A | 2023 |
Memantine/Aripiprazole Combination Alleviates Cognitive Dysfunction in Valproic Acid Rat Model of Autism: Hippocampal CREB/BDNF Signaling and Glutamate Homeostasis.
Topics: Animals; Aripiprazole; Autism Spectrum Disorder; Autistic Disorder; Brain-Derived Neurotrophic Facto | 2023 |
Retinoic acid administration normalizes aberrant microglial activation via regulating TREM2 transcription in the PFC of valproic acid induced autism rat.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Microglia; Prefrontal Cortex; Rats; Retinoic A | 2023 |
Fetal exposure to valproic acid dysregulates the expression of autism-linked genes in the developing cerebellum.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Brain; Cerebellum; Mice; Valproic Acid | 2023 |
Alteration in social interaction and tactile discrimination of juvenile autistic-like rats following tactile stimulation and whisker deprivation.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Female; Male; Pregnancy; Rats; Social Interact | 2023 |
Effects of varied‑intensity endurance exercise training on oxidative and antioxidant factors in the liver of rats with valproic acid‑induced autism.
Topics: Animals; Antioxidants; Autism Spectrum Disorder; Autistic Disorder; Catalase; Female; Humans; Liver; | 2023 |
The comparative effectiveness of metformin and risperidone in a rat model of valproic acid-induced autism, Potential role for enhanced autophagy.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Autophagy; Disease Models, Animal; Female; Hum | 2023 |
Chronic acetyl-L-carnitine treatment alleviates behavioral deficits and neuroinflammation through enhancing microbiota derived-SCFA in valproate model of autism.
Topics: Acetylcarnitine; Animals; Autism Spectrum Disorder; Autistic Disorder; Encephalitis; Female; Microbi | 2023 |
Amelioration of cognition impairments in the valproic acid-induced animal model of autism by ciproxifan, a histamine H3-receptor antagonist.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Cognition; Cognitive Dysfunc | 2023 |
Music alleviates cognitive impairments in an animal model of autism.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Cognitive Dysfunction; Disea | 2023 |
Retinoic acid supplementation ameliorates motor incoordination via RARα-CBLN2 in the cerebellum of a prenatal valproic acid-exposed rat autism model.
Topics: Animals; Ataxia; Autism Spectrum Disorder; Autistic Disorder; Cerebellum; Dietary Supplements; Disea | 2023 |
Neuroprotective Efficacy of Fisetin Against VPA-Induced Autistic Neurobehavioral Alterations by Targeting Dysregulated Redox Homeostasis.
Topics: Animals; Autistic Disorder; Disease Models, Animal; Female; Humans; Oxidation-Reduction; Pregnancy; | 2023 |
Striatal synaptic changes and behavior in adult mouse upon prenatal exposure to valproic acid.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Fema | 2023 |
G protein-coupled estrogen receptor (GPER) selective agonist G1 attenuates the neurobehavioral, molecular and biochemical alterations induced in a valproic acid rat model of autism.
Topics: Animals; Aromatase; Autism Spectrum Disorder; Autistic Disorder; Disease Models, Animal; Estradiol; | 2023 |
Syringic acid alleviates valproic acid induced autism via activation of p38 mitogen-activated protein kinase: Possible molecular approach.
Topics: Animals; Antioxidants; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Disease Models | 2023 |
N-acetylcysteine improves autism-like behavior by recovering autophagic deficiency and decreasing Notch-1/Hes-1 pathway activity.
Topics: Acetylcysteine; Animals; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Female; Humans | 2023 |
Chronic inhibition of astrocytic aquaporin-4 induces autistic-like behavior in control rat offspring similar to maternal exposure to valproic acid.
Topics: Animals; Aquaporins; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Disease Models, | 2023 |
Mice prenatally exposed to valproic acid do not show autism-related disorders when fed with polyunsaturated fatty acid-enriched diets.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Diet; Dietary Supplements; Fatty Acids, Omega- | 2023 |
Risperidone impedes glutamate excitotoxicity in a valproic acid rat model of autism: Role of ADAR2 in AMPA GluA2 RNA editing.
Topics: Adenosine Deaminase; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Autism Spect | 2023 |
The antipsychotic olanzapine reduces memory deficits and neuronal abnormalities in a male rat model of Autism.
Topics: Animals; Antipsychotic Agents; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Diseas | 2023 |
Sex-related beneficial effects of exercise on cardiac function and rhythm in autistic rats.
Topics: Animals; Autistic Disorder; Female; Humans; Male; Pregnancy; Prenatal Exposure Delayed Effects; Rats | 2023 |
Saffron and crocin ameliorate prenatal valproic acid-induced autistic-like behaviors and brain oxidative stress in the male offspring rats.
Topics: Animals; Autistic Disorder; Brain; Crocus; Disease Models, Animal; Female; Glutathione; Humans; Male | 2023 |
Prangos ferulacea (L.) ameliorates behavioral alterations, hippocampal oxidative stress markers, and apoptotic deficits in a rat model of autism induced by valproic acid.
Topics: Animals; Antioxidants; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Child; Disease | 2023 |
MA-5 ameliorates autism-like behavior in mice prenatally exposed to valproic acid.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Fema | 2023 |
The effects of valproic acid neurotoxicity on aggressive behavior in zebrafish autism model.
Topics: Aggression; Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Disease Models, | 2024 |
The possible neuroprotective role of grape seed extract on the histopathological changes of the cerebellar cortex of rats prenatally exposed to Valproic Acid: animal model of autism.
Topics: Animals; Autistic Disorder; Cerebellar Cortex; Disease Models, Animal; Female; Neuroprotective Agent | 2019 |
Gender Related Changes in Gene Expression Induced by Valproic Acid in A Mouse Model of Autism and the Correction by S-adenosyl Methionine. Does It Explain the Gender Differences in Autistic Like Behavior?
Topics: Animals; Autistic Disorder; Disease Models, Animal; Female; Gene Expression Regulation; Male; Mice; | 2019 |
Increased Expression of Kv10.2 in the Hippocampus Attenuates Valproic Acid-Induced Autism-Like Behaviors in Rats.
Topics: Animals; Anxiety; Autistic Disorder; Behavior, Animal; Biological Therapy; Ether-A-Go-Go Potassium C | 2019 |
Beneficial effects of xenon inhalation on behavioral changes in a valproic acid-induced model of autism in rats.
Topics: Administration, Inhalation; Animals; Autistic Disorder; Behavior, Animal; Female; Gait; Male; Maze L | 2019 |
Effects of single-dose antipurinergic therapy on behavioral and molecular alterations in the valproic acid-induced animal model of autism.
Topics: Animals; Anticonvulsants; Autistic Disorder; Brain; Disease Models, Animal; Female; Locomotion; Male | 2020 |
5-aminolevulinic acid inhibits oxidative stress and ameliorates autistic-like behaviors in prenatal valproic acid-exposed rats.
Topics: Aminolevulinic Acid; Animals; Anticonvulsants; Autistic Disorder; Dose-Response Relationship, Drug; | 2020 |
Quercetin prevents alterations of behavioral parameters, delta-aminolevulinic dehydratase activity, and oxidative damage in brain of rats in a prenatal model of autism.
Topics: Animals; Anticonvulsants; Autistic Disorder; Brain Chemistry; Female; Motor Activity; Neuroprotectiv | 2020 |
Changes in the Expression of SNAP-25 Protein in the Brain of Juvenile Rats in Two Models of Autism.
Topics: Animals; Autistic Disorder; Brain; Female; Male; Rats; Synaptosomal-Associated Protein 25; Thalidomi | 2020 |
Altered expression of glutamatergic and GABAergic genes in the valproic acid-induced rat model of autism: A screening test.
Topics: Animals; Autistic Disorder; Cerebellum; Cerebral Cortex; Female; GABA Agents; gamma-Aminobutyric Aci | 2020 |
Inhibition of striatal-enriched protein tyrosine phosphatase (STEP) activity reverses behavioral deficits in a rodent model of autism.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Expl | 2020 |
A heritable profile of six miRNAs in autistic patients and mouse models.
Topics: Adolescent; Adult; Animals; Anxiety; Autism Spectrum Disorder; Autistic Disorder; Child; Child, Pres | 2020 |
Vitamin A deficiency exacerbates autism-like behaviors and abnormalities of the enteric nervous system in a valproic acid-induced rat model of autism.
Topics: Animals; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Enteric Nervous System; Gastro | 2020 |
Prenatal pregabalin is associated with sex-dependent alterations in some behavioral parameters in valproic acid-induced autism in rat offspring.
Topics: Animals; Anxiety; Autistic Disorder; Behavior, Animal; Choice Behavior; Disease Models, Animal; Fema | 2020 |
Targeting PPARα in the rat valproic acid model of autism: focus on social motivational impairment and sex-related differences.
Topics: Animals; Anxiety; Autistic Disorder; Behavior, Animal; Biomarkers; Disease Models, Animal; Female; F | 2020 |
Leukemia-like megaloblastic anemia in an autistic child receiving risperidone and valproic acid.
Topics: Anemia, Megaloblastic; Autistic Disorder; Child; Humans; Leukemia; Risperidone; Valproic Acid; Vitam | 2020 |
Alterations in the autonomic nerve activities of prenatal autism model mice treated with valproic acid at different developmental stages.
Topics: Animals; Anticonvulsants; Autistic Disorder; Autonomic Pathways; Behavior, Animal; Disease Models, A | 2020 |
Systematic Analysis of Protein-Protein and Gene-Environment Interactions to Decipher the Cognitive Mechanisms of Autism Spectrum Disorder.
Topics: Autism Spectrum Disorder; Autistic Disorder; Cognition; Gene-Environment Interaction; Humans; Valpro | 2022 |
Glyoxalase 1 Inhibitor Alleviates Autism-like Phenotype in a Prenatal Valproic Acid-Induced Mouse Model.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Fema | 2020 |
Identification of a
Topics: Animals; Autistic Disorder; beta-Arrestin 2; Disease Models, Animal; Exome Sequencing; Female; Gene | 2020 |
Validation of prenatal versus postnatal valproic acid rat models of autism: A behavioral and neurobiological study.
Topics: Animals; Animals, Newborn; Apoptosis; Autistic Disorder; Brain Chemistry; Cytokines; Disease Models, | 2021 |
Metformin, valproic acid, and starvation induce seizures in a patient with partial SLC13A5 deficiency: a case of pharmaco-synergistic heterozygosity.
Topics: Adult; Amino Acid Substitution; Ammonia; Animals; Anticonvulsants; Autistic Disorder; Bipolar Disord | 2021 |
Postnatal AVP treatments prevent social deficit in adolescence of valproic acid-induced rat autism model.
Topics: Adolescent; Animals; Arginine Vasopressin; Autistic Disorder; Behavior, Animal; Disease Models, Anim | 2021 |
Transcutaneous Electrical Acupoint Stimulation in Early Life Changes Synaptic Plasticity and Improves Symptoms in a Valproic Acid-Induced Rat Model of Autism.
Topics: Acupuncture Points; Acupuncture Therapy; Age Factors; Animals; Autistic Disorder; Disease Models, An | 2020 |
Correlation of distinct behaviors to the modified expression of cerebral Shank1,3 and BDNF in two autistic animal models.
Topics: Animals; Anxiety; Autistic Disorder; Blotting, Western; Brain-Derived Neurotrophic Factor; Cerebrum; | 2021 |
Daily intake of Lactobacillus alleviates autistic-like behaviors by ameliorating the 5-hydroxytryptamine metabolic disorder in VPA-treated rats during weaning and sexual maturation.
Topics: Animals; Autistic Disorder; Behavior, Animal; Butyric Acid; Disease Models, Animal; Fatty Acids, Vol | 2021 |
Alterations in Tau Protein Level and Phosphorylation State in the Brain of the Autistic-Like Rats Induced by Prenatal Exposure to Valproic Acid.
Topics: Animals; Autistic Disorder; Biomarkers; Brain; Disease Susceptibility; Enzyme Activation; Female; Im | 2021 |
Increased volumes of lobule VI in a valproic acid model of autism are associated with worse set-shifting performance in male Long-Evan rats.
Topics: Animals; Attention; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Brain; Cerebellum | 2021 |
Maternal folic acid supplementation prevents autistic behaviors in a rat model induced by prenatal exposure to valproic acid.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Dietary Supplements; Disease | 2021 |
Vitamin A supplementation ameliorates motor incoordination via modulating RORα in the cerebellum in a valproic acid-treated rat autism model with vitamin A deficiency.
Topics: Animals; Autistic Disorder; Cerebellum; Female; Male; Nuclear Receptor Subfamily 1, Group F, Member | 2021 |
Phenotypic overlap between atopic dermatitis and autism.
Topics: Animals; Anticonvulsants; Autistic Disorder; Dermatitis, Atopic; Female; Inflammation Mediators; Maz | 2021 |
Increasing Endocannabinoid Tone Alters Anxiety-Like and Stress Coping Behaviour in Female Rats Prenatally Exposed to Valproic Acid.
Topics: Animals; Anxiety; Anxiety Disorders; Autistic Disorder; Behavior, Animal; Disease Models, Animal; En | 2021 |
Another step toward understanding brain functional connectivity alterations in autism: An Editorial Highlight for "Neurobiological substrates underlying corpus callosum hypoconnectivity and brain metabolic patterns in the valproic acid rat model of autism
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Brain; Corpus Callosum; Humans; Nerve Net; Rat | 2021 |
Behavioral improvements in a valproic acid rat model of autism following vitamin D supplementation.
Topics: Animals; Antimanic Agents; Autistic Disorder; Behavior, Animal; Dietary Supplements; Disease Models, | 2017 |
Modeling environmental risk factors of autism in mice induces IBD-related gut microbial dysbiosis and hyperserotonemia.
Topics: Animals; Autistic Disorder; Bacteria; Biodiversity; Diet; Dysbiosis; Environment; Gastrointestinal M | 2017 |
Postnatal treatment using curcumin supplements to amend the damage in VPA-induced rodent models of autism.
Topics: Animals; Anticonvulsants; Autistic Disorder; Brain; Curcumin; Dietary Supplements; Disease Models, A | 2017 |
Burst Suppression Pattern on Electroencephalogram Secondary to Valproic Acid-Induced Hyperammonemic Encephalopathy.
Topics: Adolescent; Anticonvulsants; Autistic Disorder; Brain Diseases; Electroencephalography; Epilepsy; Fe | 2017 |
N-acetylcysteine ameliorates repetitive/stereotypic behavior due to its antioxidant properties without activation of the canonical Wnt pathway in a valproic acid-induced rat model of autism.
Topics: Acetylcysteine; Animals; Antioxidants; Autistic Disorder; Behavior, Animal; beta Catenin; Brain; Glu | 2017 |
Exposure to Sodium Valproate during Pregnancy: Facial Features and Signs of Autism.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Autism Spectrum Disorder; Autistic | 2017 |
Environmental enrichment attenuates behavioral abnormalities in valproic acid-exposed autism model mice.
Topics: Animals; Anticonvulsants; Autistic Disorder; Brain; Brain-Derived Neurotrophic Factor; Dendritic Spi | 2017 |
Laser Acupuncture at HT7 Improves the Cerebellar Disorders in Valproic Acid-Rat Model of Autism.
Topics: Acupuncture Points; Acupuncture Therapy; Animals; Autistic Disorder; Cerebellar Diseases; Cerebellum | 2017 |
Oxytocin attenuates deficits in social interaction but not recognition memory in a prenatal valproic acid-induced mouse model of autism.
Topics: Animals; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Female; Hippocampus; Interpers | 2017 |
Identifying specific prefrontal neurons that contribute to autism-associated abnormalities in physiology and social behavior.
Topics: Action Potentials; Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Disease M | 2018 |
Impaired repair of DNA damage is associated with autistic-like traits in rats prenatally exposed to valproic acid.
Topics: Animals; Anxiety; Autistic Disorder; Disease Models, Animal; DNA Damage; DNA Repair; Dose-Response R | 2018 |
Modulation of sphingosine 1-phosphate (S1P) attenuates spatial learning and memory impairments in the valproic acid rat model of autism.
Topics: Analysis of Variance; Animals; Apoptosis; Autistic Disorder; Autophagy; Biomarkers; Disease Models, | 2018 |
Transcriptional and splicing dysregulation in the prefrontal cortex in valproic acid rat model of autism.
Topics: Alternative Splicing; Animals; Anticonvulsants; Autistic Disorder; Behavior, Animal; Disease Models, | 2018 |
Zinc as a therapy in a rat model of autism prenatally induced by valproic acid.
Topics: Animals; Autistic Disorder; Corpus Striatum; Disease Models, Animal; Female; Male; Neuroprotective A | 2018 |
Second-generation antipsychotic and diabetes mellitus in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Benzodiazepines; Blood Glucose; Clomipramine; D | 2017 |
Behavioral alterations in autism model induced by valproic acid and translational analysis of circulating microRNA.
Topics: Adolescent; Animals; Anticonvulsants; Antioxidants; Autistic Disorder; Behavior, Animal; Child; Chil | 2018 |
Morphometric analysis and neuroanatomical mapping of the zebrafish brain.
Topics: Animals; Animals, Genetically Modified; Autistic Disorder; Behavior, Animal; Brain; Brain Mapping; C | 2018 |
Hesperetin and it nanocrystals ameliorate social behavior deficits and oxido-inflammatory stress in rat model of autism.
Topics: Animals; Anticonvulsants; Antioxidants; Autistic Disorder; Birth Weight; Brain Chemistry; Cytokines; | 2018 |
Sex-specific autistic endophenotypes induced by prenatal exposure to valproic acid involve anandamide signalling.
Topics: Animals; Anticonvulsants; Arachidonic Acids; Autistic Disorder; Behavior, Animal; Endocannabinoids; | 2018 |
Reduced CD4 T Lymphocytes in Lymph Nodes of the Mouse Model of Autism Induced by Valproic Acid.
Topics: Animals; Autistic Disorder; CD4-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; F | 2018 |
The histamine H3R antagonist DL77 attenuates autistic behaviors in a prenatal valproic acid-induced mouse model of autism.
Topics: Animals; Anxiety; Autistic Disorder; Behavior, Animal; Brain; Choice Behavior; Cytokines; Disease Mo | 2018 |
Prenatal exposure to valproate induces sex-, age-, and tissue-dependent alterations of cholesterol metabolism: Potential implications on autism.
Topics: Age Factors; Animals; Anticonvulsants; Autistic Disorder; Brain; Cholesterol; Female; Liver; Male; M | 2019 |
Social behavior, neuroimmune markers and glutamic acid decarboxylase levels in a rat model of valproic acid-induced autism.
Topics: Animals; Autistic Disorder; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cell Adhesion Molec | 2018 |
mS-11, a mimetic of the mSin3-binding helix in NRSF, ameliorates social interaction deficits in a prenatal valproic acid-induced autism mouse model.
Topics: Animals; Autistic Disorder; Behavior, Animal; Dendritic Spines; Disease Models, Animal; Female; Hete | 2019 |
Regional and sex-dependent alterations in Purkinje cell density in the valproate mouse model of autism.
Topics: Animals; Anticonvulsants; Autistic Disorder; Cell Count; Cerebellum; Disease Models, Animal; Female; | 2019 |
The valproic acid rat model of autism presents with gut bacterial dysbiosis similar to that in human autism.
Topics: Animals; Autistic Disorder; Bacterial Typing Techniques; Disease Models, Animal; Dysbiosis; Gastroin | 2018 |
Neuroglia in the autistic brain: evidence from a preclinical model.
Topics: Animals; Autistic Disorder; Brain; Female; Male; Neuroglia; Rats; Rats, Wistar; Stereotyped Behavior | 2018 |
Benefits of Fenofibrate in prenatal valproic acid-induced autism spectrum disorder related phenotype in rats.
Topics: Animals; Anticonvulsants; Anxiety; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Br | 2019 |
The Notch signaling pathway inhibitor Dapt alleviates autism-like behavior, autophagy and dendritic spine density abnormalities in a valproic acid-induced animal model of autism.
Topics: Animals; Atrophy; Autistic Disorder; Autophagy; Beclin-1; Behavior, Animal; Cerebellum; Dendritic Sp | 2019 |
Purkinje cell number-correlated cerebrocerebellar circuit anomaly in the valproate model of autism.
Topics: Animals; Autistic Disorder; Calbindins; Cell Count; Disease Models, Animal; Female; Magnetic Resonan | 2019 |
[Improvement of a mouse model of valproic acid-induced autism].
Topics: Animals; Autistic Disorder; Disease Models, Animal; Female; Mice; Pregnancy; Prenatal Exposure Delay | 2019 |
Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism.
Topics: Adolescent; Adult; Anticonvulsants; Autistic Disorder; Child; Child Development Disorders, Pervasive | 2013 |
Risks of in utero exposure to valproate.
Topics: Anticonvulsants; Autistic Disorder; Child Development Disorders, Pervasive; Epilepsy; Female; Humans | 2013 |
Valproate in pregnancy linked to autism in children.
Topics: Anticonvulsants; Autistic Disorder; Denmark; Epilepsy; Female; Humans; Incidence; Infant, Newborn; P | 2013 |
Alterations in the endocannabinoid system in the rat valproic acid model of autism.
Topics: Amidohydrolases; Animals; Autistic Disorder; Behavior, Animal; Brain; Disease Models, Animal; Endoca | 2013 |
Comparative gene expression analysis of the amygdala in autistic rat models produced by pre- and post-natal exposures to valproic acid.
Topics: Amygdala; Animals; Animals, Newborn; Anxiety; Autistic Disorder; Behavior, Animal; Disease Models, A | 2013 |
Possible ameliorative effect of breastfeeding and the uptake of human colostrum against coeliac disease in autistic rats.
Topics: Animal Nutritional Physiological Phenomena; Animals; Animals, Suckling; Autistic Disorder; Autoantib | 2013 |
Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Autistic Disorder; Central Nervous System Stimula | 2013 |
Treadmill exercise ameliorates motor disturbance through inhibition of apoptosis in the cerebellum of valproic acid-induced autistic rat pups.
Topics: Animals; Animals, Newborn; Apoptosis; Autistic Disorder; bcl-2-Associated X Protein; Caspase 3; Cell | 2013 |
Increased hippocampal cell density and enhanced spatial memory in the valproic acid rat model of autism.
Topics: Animals; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Female; GABA Agents; Hippocamp | 2013 |
5-HT1A-receptor agonist modified amygdala activity and amygdala-associated social behavior in a valproate-induced rat autism model.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amygdala; Animals; Autistic Disorder; Behavior, Animal; Cina | 2013 |
Melatonin reverses the decreases in hippocampal protein serine/threonine kinases observed in an animal model of autism.
Topics: Analysis of Variance; Animals; Antioxidants; Autistic Disorder; Behavior, Animal; Calcium-Calmodulin | 2014 |
Prenatal valproate exposure is associated with autism spectrum disorder and childhood autism.
Topics: Anticonvulsants; Autistic Disorder; Child Development Disorders, Pervasive; Epilepsy; Female; Humans | 2013 |
Prenatal exposure to sodium valproate is associated with increased risk of childhood autism and autistic spectrum disorder.
Topics: Anticonvulsants; Autistic Disorder; Child Development Disorders, Pervasive; Epilepsy; Female; Humans | 2014 |
Valproate use during pregnancy was linked to autism spectrum disorder and childhood autism in offspring.
Topics: Anticonvulsants; Autistic Disorder; Child Development Disorders, Pervasive; Epilepsy; Female; Humans | 2013 |
Pax6-dependent cortical glutamatergic neuronal differentiation regulates autism-like behavior in prenatally valproic acid-exposed rat offspring.
Topics: Animals; Autistic Disorder; Cell Differentiation; Cells, Cultured; Cerebral Cortex; Eye Proteins; Fe | 2014 |
Combined prenatal and postnatal butyl paraben exposure produces autism-like symptoms in offspring: comparison with valproic acid autistic model.
Topics: Animals; Autistic Disorder; Female; Male; Maternal Exposure; Models, Theoretical; Parabens; Pregnanc | 2013 |
Autism's cancer connection: the anti-proliferation hypothesis and why it may matter.
Topics: Antineoplastic Agents; Autistic Disorder; Epigenetic Repression; Gene Expression Regulation, Neoplas | 2014 |
An unusual cause of gross hematuria: questions and answers.
Topics: Autistic Disorder; Child; Cystitis; Eosinophilia; GABA Agents; Hematuria; Humans; Male; Valproic Aci | 2015 |
Increased BDNF expression in fetal brain in the valproic acid model of autism.
Topics: Animals; Autistic Disorder; Brain; Brain-Derived Neurotrophic Factor; Female; Fetus; Maternal-Fetal | 2014 |
Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring.
Topics: Animals; Autistic Disorder; Behavior, Animal; Bumetanide; Chlorides; Cytoprotection; Disease Models, | 2014 |
Degraded auditory processing in a rat model of autism limits the speech representation in non-primary auditory cortex.
Topics: Acoustic Stimulation; Animals; Auditory Cortex; Auditory Perception; Autistic Disorder; Disease Mode | 2014 |
Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism.
Topics: Anticonvulsants; Autistic Disorder; Child Development Disorders, Pervasive; Epilepsy; Female; Humans | 2014 |
Ameliorating effect of piperine on behavioral abnormalities and oxidative markers in sodium valproate induced autism in BALB/C mice.
Topics: Alkaloids; Animals; Anxiety; Autistic Disorder; Benzodioxoles; Biomarkers; Brain; Cognition; Disease | 2014 |
Valproate and folic acid in pregnancy: associations with autism.
Topics: Autistic Disorder; Epilepsy; Female; Folic Acid; Humans; Pregnancy; Prenatal Exposure Delayed Effect | 2014 |
Long-term valproic acid exposure increases the number of neocortical neurons in the developing rat brain. A possible new animal model of autism.
Topics: Animals; Anticonvulsants; Autistic Disorder; Cell Count; Disease Models, Animal; Female; Lactation; | 2014 |
Subchronic treatment of donepezil rescues impaired social, hyperactive, and stereotypic behavior in valproic acid-induced animal model of autism.
Topics: Acetylcholinesterase; Animals; Autistic Disorder; Behavior, Animal; Blotting, Western; Cells, Cultur | 2014 |
Chronic treatment with valproic acid or sodium butyrate attenuates novel object recognition deficits and hippocampal dendritic spine loss in a mouse model of autism.
Topics: Acetylation; Animals; Autistic Disorder; Butyric Acid; CA1 Region, Hippocampal; Dendritic Spines; Di | 2014 |
Resveratrol prevents social deficits in animal model of autism induced by valproic acid.
Topics: Animals; Anti-Inflammatory Agents; Autistic Disorder; Female; Male; Maternal Exposure; Molecular Dyn | 2014 |
MeCP2 Modulates Sex Differences in the Postsynaptic Development of the Valproate Animal Model of Autism.
Topics: Animals; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Female; Methyl-CpG-Binding Pro | 2016 |
Interplay between pro-inflammatory cytokines and brain oxidative stress biomarkers: evidence of parallels between butyl paraben intoxication and the valproic acid brain physiopathology in autism rat model.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Animals; Autistic Disorder; Biomarkers; Brain; Brai | 2015 |
Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy.
Topics: Age of Onset; Anticonvulsants; Autistic Disorder; Benzodiazepines; Cadherins; Child; Clobazam; Cogni | 2015 |
Tactile stimulation improves neuroanatomical pathology but not behavior in rats prenatally exposed to valproic acid.
Topics: Amygdala; Animals; Autistic Disorder; Behavior, Animal; Dendrites; Dendritic Spines; Disease Models, | 2015 |
Effects of an H3R antagonist on the animal model of autism induced by prenatal exposure to valproic acid.
Topics: Animals; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Female; Histamine Antagonists; | 2015 |
Pancreatic response to gold nanoparticles includes decrease of oxidative stress and inflammation in autistic diabetic model.
Topics: Animals; Antioxidants; Autistic Disorder; Diabetes Mellitus, Experimental; Disease Models, Animal; F | 2015 |
Decreased mTOR signaling pathway in human idiopathic autism and in rats exposed to valproic acid.
Topics: Adolescent; Adult; Animals; Anticonvulsants; Autistic Disorder; Child; Child, Preschool; Disease Mod | 2015 |
Association between SNAP-25 gene polymorphisms and cognition in autism: functional consequences and potential therapeutic strategies.
Topics: Adolescent; Amphetamine; Animals; Autistic Disorder; Behavior, Animal; Central Nervous System Stimul | 2015 |
Astaxanthin improves behavioral disorder and oxidative stress in prenatal valproic acid-induced mice model of autism.
Topics: Animals; Anxiety; Autistic Disorder; Brain; Catalase; Disease Models, Animal; Female; Glutathione; L | 2015 |
Analytical strategies for the marble burying test: avoiding impossible predictions and invalid p-values.
Topics: Analysis of Variance; Animals; Anxiety; Autistic Disorder; Behavior, Animal; Calcium Carbonate; Dise | 2015 |
Differential Local Connectivity and Neuroinflammation Profiles in the Medial Prefrontal Cortex and Hippocampus in the Valproic Acid Rat Model of Autism.
Topics: Animals; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Exploratory Behavior; Female; | 2015 |
Reduced prefrontal dopaminergic activity in valproic acid-treated mouse autism model.
Topics: Animals; Autistic Disorder; Biogenic Monoamines; Corpus Striatum; Disease Models, Animal; Dopamine; | 2015 |
Study of the serum levels of polyunsaturated fatty acids and the expression of related liver metabolic enzymes in a rat valproate-induced autism model.
Topics: Acetyltransferases; Animals; Anticonvulsants; Autistic Disorder; bcl-2-Associated X Protein; Caspase | 2015 |
Characterization of in utero valproic acid mouse model of autism by local field potential in the hippocampus and the olfactory bulb.
Topics: Animals; Anticonvulsants; Autistic Disorder; CA1 Region, Hippocampal; Exploratory Behavior; Female; | 2015 |
Psychoactive pharmaceuticals as environmental contaminants may disrupt highly inter-connected nodes in an Autism-associated protein-protein interaction network.
Topics: Animals; Anticonvulsants; Antidepressive Agents, Second-Generation; Autistic Disorder; Brain; Carbam | 2015 |
Elevated microRNA-181c and microRNA-30d levels in the enlarged amygdala of the valproic acid rat model of autism.
Topics: Amygdala; Animals; Autistic Disorder; Disease Models, Animal; MicroRNAs; Neurons; Rats; Social Behav | 2015 |
Putative Microcircuit-Level Substrates for Attention Are Disrupted in Mouse Models of Autism.
Topics: Action Potentials; Animals; Attention; Autistic Disorder; Calcium; Disease Models, Animal; Fluoxetin | 2016 |
Indifference of marmosets with prenatal valproate exposure to third-party non-reciprocal interactions with otherwise avoided non-reciprocal individuals.
Topics: Animals; Autistic Disorder; Behavior, Animal; Callithrix; Disease Models, Animal; Female; Humans; In | 2015 |
Effects of prenatal exposure to valproic acid on the development of juvenile-typical social play in rats.
Topics: Animals; Autistic Disorder; Behavior, Animal; Communication; Disease Models, Animal; Female; Male; P | 2015 |
Laser Acupuncture Improves Behavioral Disorders and Brain Oxidative Stress Status in the Valproic Acid Rat Model of Autism.
Topics: Acupuncture Points; Acupuncture Therapy; Animals; Autistic Disorder; Brain; Catalase; Disease Models | 2015 |
[Effect of sulindac on improving autistic behaviors in rats].
Topics: Animals; Autistic Disorder; beta Catenin; Disease Models, Animal; Down-Regulation; Female; Glycogen | 2015 |
Minocycline ameliorates prenatal valproic acid induced autistic behaviour, biochemistry and blood brain barrier impairments in rats.
Topics: Animals; Autistic Disorder; Blood-Brain Barrier; Brain; Capillary Permeability; Central Nervous Syst | 2016 |
Neuroprotective effects of docosahexaenoic acid on hippocampal cell death and learning and memory impairments in a valproic acid-induced rat autism model.
Topics: Animals; Anticonvulsants; Autistic Disorder; Caspase 3; Cell Death; Disease Models, Animal; Docosahe | 2016 |
Improvement by methylphenidate and atomoxetine of social interaction deficits and recognition memory impairment in a mouse model of valproic acid-induced autism.
Topics: Animals; Atomoxetine Hydrochloride; Autistic Disorder; Behavior, Animal; Dendritic Spines; Disease M | 2016 |
[A girl with foetal valproate syndrome and autism spectrum disorder].
Topics: Anticonvulsants; Autistic Disorder; Child; Child Development Disorders, Pervasive; Epilepsy; Female; | 2016 |
Alteration of spontaneous spectral powers and coherences of local field potential in prenatal valproic acid mouse model of autism.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Expl | 2015 |
Memantine ameliorates autistic behavior, biochemistry & blood brain barrier impairments in rats.
Topics: Animals; Autistic Disorder; Blood-Brain Barrier; Brain; Disease Models, Animal; Excitatory Amino Aci | 2016 |
Autistic-Like Behaviors, Oxidative Stress Status, and Histopathological Changes in Cerebellum of Valproic Acid Rat Model of Autism Are Improved by the Combined Extract of Purple Rice and Silkworm Pupae.
Topics: Animals; Autistic Disorder; Behavior, Animal; Bombyx; Cerebellum; Complex Mixtures; Disease Models, | 2016 |
Early Behavioral Abnormalities and Perinatal Alterations of PTEN/AKT Pathway in Valproic Acid Autism Model Mice.
Topics: Animals; Autistic Disorder; Behavior, Animal; Dendritic Spines; Disease Models, Animal; Female; Hipp | 2016 |
Validation of reference genes for quantitative real-time PCR in valproic acid rat models of autism.
Topics: Animals; Autistic Disorder; Female; Gene Expression Profiling; Hippocampus; Male; Prefrontal Cortex; | 2016 |
Prenatal Exposure to Histone Deacetylase Inhibitors Affects Gene Expression of Autism-Related Molecules and Delays Neuronal Maturation.
Topics: Animals; Autistic Disorder; Female; Gene Expression Regulation, Developmental; Histone Deacetylase I | 2016 |
Functional Genomic Analyses Identify Pathways Dysregulated in Animal Model of Autism.
Topics: Animals; Animals, Newborn; Autistic Disorder; Disease Models, Animal; Environment; Enzyme Inhibitors | 2016 |
Psychoactive pharmaceuticals at environmental concentrations induce in vitro gene expression associated with neurological disorders.
Topics: Animals; Autistic Disorder; Carbamazepine; Cell Line, Tumor; Environmental Pollutants; Fluoxetine; G | 2016 |
Alleviation of N-Methyl-D-Aspartate Receptor-Dependent Long-Term Depression via Regulation of the Glycogen Synthase Kinase-3β Pathway in the Amygdala of a Valproic Acid-Induced Animal Model of Autism.
Topics: Animals; Autistic Disorder; Depression; Disease Models, Animal; Enzyme Inhibitors; Glycogen Synthase | 2017 |
Pharmacological inhibition of fatty acid amide hydrolase attenuates social behavioural deficits in male rats prenatally exposed to valproic acid.
Topics: Amidohydrolases; Animals; Arachidonic Acids; Autistic Disorder; Behavior, Animal; Disease Models, An | 2016 |
Beneficial Effects of Co-Ultramicronized Palmitoylethanolamide/Luteolin in a Mouse Model of Autism and in a Case Report of Autism.
Topics: Amides; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Autistic Disorder; Brain | 2017 |
Human adipose-derived stem cells ameliorate repetitive behavior, social deficit and anxiety in a VPA-induced autism mouse model.
Topics: Adipose Tissue; Animals; Animals, Newborn; Anxiety; Autistic Disorder; Cumulative Trauma Disorders; | 2017 |
Comparative efficacy of alpha-linolenic acid and gamma-linolenic acid to attenuate valproic acid-induced autism-like features.
Topics: alpha-Linolenic Acid; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Anticonvul | 2017 |
Interstimulus interval (ISI) discrimination of the conditioned eyeblink response in a rodent model of autism.
Topics: Animals; Autistic Disorder; Body Weight; Conditioning, Eyelid; Data Interpretation, Statistical; Dis | 2009 |
Altered morphology of motor cortex neurons in the VPA rat model of autism.
Topics: Age Factors; Animals; Autistic Disorder; Dendrites; Disease Models, Animal; Female; Male; Motor Cort | 2008 |
Common increase of GATA-3 level in PC-12 cells by three teratogens causing autism spectrum disorders.
Topics: Animals; Autistic Disorder; Ethanol; GATA3 Transcription Factor; Gene Expression Profiling; PC12 Cel | 2009 |
Observation of fetal brain in a rat valproate-induced autism model: a developmental neurotoxicity study.
Topics: Animals; Anticonvulsants; Autistic Disorder; Brain; Disease Models, Animal; Female; Fetus; Humans; M | 2009 |
Nonexploratory movement and behavioral alterations in a thalidomide or valproic acid-induced autism model rat.
Topics: Age Factors; Animals; Autistic Disorder; Disease Models, Animal; Exploratory Behavior; Female; Inter | 2010 |
Behavior and serotonergic disorders in rats exposed prenatally to valproate: a model for autism.
Topics: Animals; Autistic Disorder; Behavior, Animal; Brain; Disease Models, Animal; Female; GABA Agents; Hi | 2010 |
Animal model of autism using GSTM1 knockout mice and early post-natal sodium valproate treatment.
Topics: Age Factors; Animals; Animals, Newborn; Autistic Disorder; Brain; Brain Chemistry; Cell Count; Disea | 2010 |
Increase in valproic acid levels during riluzole treatment in an adolescent with autism.
Topics: Adolescent; Autistic Disorder; Female; Humans; Riluzole; Valproic Acid | 2010 |
Behavioral and molecular changes in the mouse in response to prenatal exposure to the anti-epileptic drug valproic acid.
Topics: Animals; Anticonvulsants; Autistic Disorder; Behavior, Animal; Brain; Brain-Derived Neurotrophic Fac | 2010 |
Altering the trajectory of early postnatal cortical development can lead to structural and behavioural features of autism.
Topics: Animals; Anticonvulsants; Autistic Disorder; Behavior, Animal; Cerebral Cortex; Cues; Electrophysiol | 2010 |
Correlation between EEG abnormalities and symptoms of autism spectrum disorder (ASD).
Topics: Adolescent; Age of Onset; Aging; Anticonvulsants; Asperger Syndrome; Autistic Disorder; Brain Mappin | 2010 |
Rise in brain GABA to further stress the metabolic link between valproate and creatine.
Topics: Ammonia; Autistic Disorder; Brain; Creatine; Humans; Valproic Acid | 2011 |
Validating γ oscillations and delayed auditory responses as translational biomarkers of autism.
Topics: Animals; Animals, Newborn; Auditory Perception; Autistic Disorder; Behavior, Animal; Biomarkers; Bra | 2010 |
The critical period of valproate exposure to induce autistic symptoms in Sprague-Dawley rats.
Topics: Animals; Anticonvulsants; Autistic Disorder; Disease Models, Animal; Electroshock; Female; Fetus; Gl | 2011 |
[Staring episodes in children with developmental disorders: epilepsy or behaviour?].
Topics: Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Child; Child Behavior; Diagnosis, | 2011 |
Morphological abnormalities of embryonic cranial nerves after in utero exposure to valproic acid: implications for the pathogenesis of autism with multiple developmental anomalies.
Topics: Abnormalities, Multiple; Animals; Anticonvulsants; Autistic Disorder; Cranial Nerves; Disease Models | 2011 |
Epigenetic, polymorphic and mutational (Αα167Arg→Lys) contribution to a functionally abnormal fibrinogen.
Topics: Autistic Disorder; Epigenesis, Genetic; Family; Fibrinogens, Abnormal; Humans; Male; Mutation; Polym | 2011 |
Malformation of the superior olivary complex in an animal model of autism.
Topics: Animals; Auditory Pathways; Auditory Perceptual Disorders; Autistic Disorder; Disease Models, Animal | 2011 |
Animal model of autism induced by prenatal exposure to valproate: behavioral changes and liver parameters.
Topics: Aging; Alanine Transaminase; Animals; Anticonvulsants; Aspartate Aminotransferases; Autistic Disorde | 2011 |
Amelioration of behavioral aberrations and oxidative markers by green tea extract in valproate induced autism in animals.
Topics: Animals; Autistic Disorder; Behavior, Animal; Brain; Camellia sinensis; Disease Models, Animal; Fema | 2011 |
mGluR5-antagonist mediated reversal of elevated stereotyped, repetitive behaviors in the VPA model of autism.
Topics: Animals; Anti-Anxiety Agents; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Female; G | 2011 |
Autism-like behaviours with transient histone hyperacetylation in mice treated prenatally with valproic acid.
Topics: Acetylation; Animals; Autistic Disorder; Cell Movement; Cerebral Cortex; Female; Histones; Interpers | 2013 |
Bacopa monniera (L.) Wettst ameliorates behavioral alterations and oxidative markers in sodium valproate induced autism in rats.
Topics: Animals; Autistic Disorder; Bacopa; Behavior, Animal; Biomarkers; Female; Male; Oxidative Stress; Pl | 2012 |
Sensory and motor characterization in the postnatal valproate rat model of autism.
Topics: Animals; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Feeding Behavior; Female; GABA | 2012 |
Animal model of autism induced by prenatal exposure to valproate: altered glutamate metabolism in the hippocampus.
Topics: Animals; Anticonvulsants; Astrocytes; Autistic Disorder; Disease Models, Animal; Female; Glutamic Ac | 2013 |
Impairment of cortical GABAergic synaptic transmission in an environmental rat model of autism.
Topics: Animals; Antimanic Agents; Autistic Disorder; Biophysics; Disease Models, Animal; Electric Stimulati | 2013 |
The amygdala excitatory/inhibitory balance in a valproate-induced rat autism model.
Topics: Amygdala; Analysis of Variance; Animals; Autistic Disorder; Conditioning, Operant; Excitatory Postsy | 2013 |
Increased monoamine concentration in the brain and blood of fetal thalidomide- and valproic acid-exposed rat: putative animal models for autism.
Topics: Animals; Autistic Disorder; Biogenic Monoamines; Brain; Female; Pregnancy; Rats; Rats, Sprague-Dawle | 2002 |
[Landau-Kleffner and autistic regression: the importance of differential diagnosis].
Topics: Anticonvulsants; Autistic Disorder; Child, Preschool; Diagnosis, Differential; Electroencephalograph | 2002 |
Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism.
Topics: Acoustic Stimulation; Animals; Anticonvulsants; Attention; Autistic Disorder; Behavior, Animal; Disc | 2005 |
Environmental enrichment reverses behavioral alterations in rats prenatally exposed to valproic acid: issues for a therapeutic approach in autism.
Topics: Animals; Anticonvulsants; Anxiety; Autistic Disorder; Behavior, Animal; Environment; Exploratory Beh | 2006 |
Frequency of epileptiform EEG abnormalities in a sequential screening of autistic patients with no known clinical epilepsy from 1996 to 2005.
Topics: Adolescent; Adult; Anticonvulsants; Autistic Disorder; Child; Child, Preschool; Electroencephalograp | 2006 |
A new neurobehavioral model of autism in mice: pre- and postnatal exposure to sodium valproate.
Topics: Animals; Animals, Newborn; Anticonvulsants; Attention; Autistic Disorder; Disease Models, Animal; Do | 2006 |
Discrimination learning and reversal of the conditioned eyeblink reflex in a rodent model of autism.
Topics: Analysis of Variance; Animals; Autistic Disorder; Conditioning, Eyelid; Discrimination Learning; Fem | 2007 |
Abnormality of circadian rhythm accompanied by an increase in frontal cortex serotonin in animal model of autism.
Topics: Animals; Animals, Newborn; Autistic Disorder; Behavior, Animal; Chronobiology Disorders; Disease Mod | 2007 |
The challenges of psychopharmacological management of children with severe developmental disabilities.
Topics: Anticonvulsants; Antipsychotic Agents; Autistic Disorder; Caregivers; Child; Developmental Disabilit | 2006 |
Prenatal exposure to valproic acid disturbs the enkephalinergic system functioning, basal hedonic tone, and emotional responses in an animal model of autism.
Topics: Animals; Anticonvulsants; Anxiety; Autistic Disorder; Basal Ganglia; Conditioning, Classical; Diseas | 2007 |
Abnormal fear conditioning and amygdala processing in an animal model of autism.
Topics: Amygdala; Analysis of Variance; Animals; Animals, Newborn; Anticonvulsants; Autistic Disorder; Behav | 2008 |
Hyperconnectivity of local neocortical microcircuitry induced by prenatal exposure to valproic acid.
Topics: Animals; Anticonvulsants; Autistic Disorder; Cell Count; Disease Models, Animal; Female; Male; Neoco | 2008 |
Early intervention for the ocular and neurodevelopmental sequelae of Fetal Valproate Syndrome.
Topics: Abnormalities, Drug-Induced; Amblyopia; Anticonvulsants; Autistic Disorder; Child, Preschool; Cranio | 2007 |
Swim stress exaggerates the hyperactive mesocortical dopamine system in a rodent model of autism.
Topics: Age Factors; Animals; Animals, Newborn; Anticonvulsants; Autistic Disorder; Behavior, Animal; Chroma | 2008 |
Gender-specific behavioral and immunological alterations in an animal model of autism induced by prenatal exposure to valproic acid.
Topics: Animals; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Female; Immunity, Innate; Male | 2008 |
Fetal valproate syndrome: clinical and neuro-developmental features in two sibling pairs.
Topics: Adult; Autistic Disorder; Child, Preschool; Clonazepam; Developmental Disabilities; Epilepsy; Family | 1994 |
Autism: electroencephalogram abnormalities and clinical improvement with valproic acid.
Topics: Autistic Disorder; Brain; Child; Child, Preschool; Electroencephalography; Epilepsy; Female; Humans; | 1994 |
Hyperkinesias in a prepubertal boy with autistic disorder treated with haloperidol and valproic acid.
Topics: Anti-Dyskinesia Agents; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Autistic Dis | 1997 |
Valproic acid treatment of epilepsy in autistic twins.
Topics: Anticonvulsants; Autistic Disorder; Child, Preschool; Developmental Disabilities; Diseases in Twins; | 1997 |
A male with fetal valproate syndrome and autism.
Topics: Anticonvulsants; Audiology; Autistic Disorder; Child, Preschool; Developmental Disabilities; Female; | 1997 |
Medication-induced hypomania in Asperger's disorder.
Topics: Antimanic Agents; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Bipolar Disorder | 1998 |
Intravenous valproate for rapid stabilization of agitation in neuropsychiatric disorders.
Topics: Aggression; Anticonvulsants; Autistic Disorder; Child; Female; Humans; Infusions, Intravenous; Psych | 1998 |
Fetal valproate syndrome and autism: additional evidence of an association.
Topics: Autistic Disorder; Child; Child, Preschool; Developmental Disabilities; Epilepsy; Female; Follow-Up | 2001 |
'Foetal valproate syndrome and autism: additional evidence of an association'.
Topics: Abnormalities, Drug-Induced; Autistic Disorder; Child; Epilepsy, Generalized; Female; Humans; Male; | 2001 |
The use of valproate in the treatment of mentally retarded persons with typical and atypical bipolar disorders.
Topics: Adult; Autistic Disorder; Bipolar Disorder; Chronic Disease; Female; Follow-Up Studies; Fragile X Sy | 1989 |